Document:

SUBSCRIPTION AGREEMENT

 

Cerulean Group, Inc.

Krizikova 22

Prague 8, 18600

Czech Republic

 

This Subscription Agreement (this “Agreement”)
has been executed by the subscriber set forth on the signature page hereof (the “Subscriber”) in connection
with the private placement offering (the “Offering”) of a minimum of $10,000,000 (the “Minimum
Offering”) and a maximum of $15,000,000 (the “Maximum Offering”) of Units of securities
(the “Units”), plus up to an additional $5,000,000 of Units to cover over-allotments, issued by Cerulean
Group, Inc., a Nevada corporation (the “Company”), at a purchase price of $1.00 per Unit (the “Purchase
Price”). Each Unit consists of (i) one share of the Company’s common stock, par value $0.001 per share (“Common
Stock”), and (ii) a warrant, substantially in the form of Exhibit A hereto (the “Warrant”),
representing the right to purchase one share of Common Stock, exercisable from issuance until five (5) years after the initial
Closing of the Offering at an exercise price of $2.00 per share. This subscription is being submitted to you in accordance with
and subject to the terms and conditions described in this Agreement, the Confidential and Non-Binding Summary Term Sheet of the
Company dated June [___], 2014, relating to the Offering (as the same may be amended or supplemented, the “Term Sheet”),
the Preliminary Confidential Private Placement Memorandum of the Company dated [__________], 2014 (as the same may be amended or
supplemented, the “PPM”), and any other Disclosure Materials (as defined below). The minimum subscription
is $25,000 (25,000 Units). The Company may accept subscriptions for less than $25,000 in its sole discretion.

 

The Units being subscribed for pursuant to
this Agreement have not been registered under the Securities Act of 1933, as amended (the “Securities Act”).
The Offering is being made on a reasonable best efforts basis to “accredited investors,” as defined in Regulation D
under the Securities Act.

 

The Units are being offered and sold in connection
with a reverse triangular merger (the “Merger”) between a subsidiary of the Company and Enumeral Biomedical
Corp., a Delaware corporation (“Enumeral”), and certain other transactions, on the terms and conditions
described in the PPM, pursuant to which Enumeral will become a wholly owned subsidiary of the Company, and all of the outstanding
Enumeral preferred and common stock will be converted into shares of the Company’s Common Stock, and Enumeral stock options
and warrants will be converted into options and warrants to purchase shares of the Company’s Common Stock, as further described
in the PPM. Prior to the first Closing (as defined below), the Company intends to change its name to “Enumeral Biomedical
Holdings, Inc.” or another name that reflects its intended new business, and to reincorporate the Company from a Nevada corporation
to a Delaware corporation.

 

The undersigned acknowledges receipt of a copy
of the Registration Rights Agreement, substantially in the form of Exhibit B hereto (the “Registration Rights
Agreement”) and the Voting Agreement, substantially in the form of Exhibit C hereto (the “Voting
Agreement”).

 

Each closing of the Offering (a “Closing,”
and the date on which such Closing occurs hereinafter referred to as the “Closing Date”) shall take place
at the offices of Crone Kline Rinde LLP, at 488 Madison Avenue, New York, New York 10022 (or such other place as is mutually agreed
to by the Company and the Placement Agent (as defined below)).

 

    	 

    	 

    

 

The initial Closing will not occur unless:

 

		a.	funds deposited in escrow as described in Section 2(b) below equal at least the Minimum Offering,
and corresponding documentation with respect to such amounts has been delivered by Subscribers as described in Section 2(a) below;
and

 

		b.	the Merger shall have been effected (or is simultaneously effected).

 

Thereafter, the Company may conduct one or
more additional Closings for the sale of the Units until the termination of the Offering. Unless terminated earlier by the Company,
the Offering shall continue until July 31, 2014, which date may be extended until September 15, 2014, by the Company, without notice
to any Subscriber, past, current or prospective.

 

The PPM, the Term Sheet, and any supplement
or amendment thereto, and any disclosure schedule or other information document, delivered to the Subscriber prior to Subscriber’s
execution of this Agreement, and any such document delivered to the Subscriber after Subscriber’s execution of this Agreement
and prior to the Closing of the Subscriber’s subscription hereunder, are collectively referred to as the “Disclosure
Materials.”

 

		1.	Subscription. The undersigned Subscriber hereby subscribes to purchase the number of Units
set forth on the Omnibus Signature Page attached hereto, for the aggregate Purchase Price as set forth on such Omnibus Signature
Page, subject to the terms and conditions of this Agreement and on the basis of the representations, warranties, covenants and
agreements contained herein.

 

		2.	Subscription Procedure. To complete a subscription for the Units, the Subscriber must fully
comply with the subscription procedure provided in this Section on or before the Closing Date.

 

		a.	Subscription Documents. On or before the Closing Date, the Subscriber shall review, complete
and execute the Omnibus Signature Page to this Agreement, the Investor Profile, Anti-Money Laundering Form and Investor Certification,
attached hereto following the Omnibus Signature Page (collectively, the “Subscription Documents”), and
deliver the Subscription Documents to the Company’s attorneys, Crone Kline Rinde LLP,
LLP (“CKR”), at the address set forth under the caption “How to subscribe for Units in
the private offering of Cerulean Group, Inc.” below. Executed documents may be delivered to CKR
by facsimile or electronic mail (e-mail), if the Subscriber delivers the original copies of the documents to CKR
as soon as practicable thereafter.

 

		b.	Purchase Price. Simultaneously with the delivery of the Subscription Documents to
CKR as provided herein, and in any event on or prior to the Closing Date, the Subscriber
shall deliver to U.S. Bank National Association, a national banking association, in its capacity as escrow agent (the “Escrow
Agent”), the full Purchase Price by certified or other bank check or by wire transfer of immediately available funds,
pursuant to the instructions set forth under the caption “How to subscribe for Units in the private offering of Cerulean
Group, Inc.” below. Such funds will be held for the Purchaser’s benefit and will be returned promptly, without
interest or offset, if this Subscription Agreement is not accepted by the Company or the Offering is terminated pursuant to its
terms by the Company prior to the Closing as defined herein.

 

		c.	Company Discretion. The Subscriber understands and agrees that the Company in its sole discretion
reserves the right to accept or reject this or any other subscription for Units, in whole or in part, notwithstanding prior receipt
by the Subscriber of notice of acceptance of this subscription. The Company shall have no obligation hereunder until the Company
shall execute and deliver to the Subscriber an executed copy of this Agreement. If this subscription is rejected in whole, or the
offering of Units is terminated, all funds received from the Subscriber will be returned without interest or offset, and this Agreement
shall thereafter be of no further force or effect. If this subscription is rejected in part, the funds for the rejected portion
of this subscription will be returned without interest or offset, and this Agreement will continue in full force and effect to
the extent this subscription was accepted.

 

    	2

    	 

    

 

		3.	Placement Agent. EDI Financial, Inc., a broker-dealer licensed with FINRA, has been engaged
on an exclusive basis as placement agent (the “Placement Agent”) for the Offering on a reasonable best
efforts basis. The Placement Agent and its sub-agents will be paid at closing a cash commission of 10% of funds raised from investors
(including current Enumeral stockholders) in the Offering and will receive warrants to purchase a number of shares of Common Stock
equal to 10% of the number of Units sold in the Offering to investors (including current Enumeral stockholders), with a term of
five (5) years and at an exercise price of $1.00 per share (the “Placement Agent Warrants”). Any sub-agent
of the Placement Agent that introduces investors to the Offering will be entitled to share in the cash fees and Placement Agent
Warrants attributable to those investors as described above, pursuant to the terms of an executed sub-agent agreement).

 

		4.	Representations and Warranties of the Company. The Company hereby represents and warrants
to the Subscriber the following:

 

		a)	Organization and Qualification. The Company is a corporation
duly organized and validly existing in good standing under the laws of the jurisdiction of its formation, and the Company and,
after the Merger, each of its subsidiaries, has the requisite corporate power to own its properties and to carry on its business
as now being conducted. Prior to the Merger, the Company does not have any subsidiaries. The Company is and, after the Merger,
each of its subsidiaries will be duly qualified as a foreign corporation to do business and is in good standing in every jurisdiction
in which the nature of the business conducted by it makes such qualification necessary, except to the extent that the failure to
be so qualified or be in good standing would not have a material adverse effect on the assets, business, condition (financial or
otherwise), results of operations or future prospects of the Company and its Subsidiaries taken as a whole (a “Material
Adverse Effect”). Each subsidiary of the Company, after giving effect to the Merger, is identified on Schedule
4a attached hereto. (For purposes of the representations and warranties contained in this
Section 4, the term “Subsidiary” as applied to the Company includes Enumeral and its subsidiaries on
a pro forma basis giving effect to the Merger.

 

		b)	Authorization, Enforcement, Compliance with Other Instruments.
(i) The Company has the requisite corporate power and authority to enter into and perform its obligations under this Agreement,
the Warrants, the Registration Rights Agreement and each of the other agreements and documents that are exhibits hereto or thereto
or are contemplated hereby or thereby or necessary or desirable to effect the transactions contemplated hereby or thereby (the
“Transaction Documents”) and to issue the shares of Common Stock contained in the Units (the “Shares”)
and the Warrants, and the shares of Common Stock issuable upon exercise of the Warrants (the “Warrant Shares”),
in accordance with the terms hereof and thereof, (ii) the execution and delivery by the Company of each of the Transaction Documents
and the consummation by it of the transactions contemplated hereby and thereby, including, without limitation, the issuance of
the Shares, the Warrants and the Warrant Shares, have been, or will be at the time of
execution of such Transaction Document, duly authorized by the Company’s Board of Directors, and no further consent or authorization
is, or will be at the time of execution of such Transaction Document, required by the Company, its respective Board of Directors
or its stockholders, (iii) each of the Transaction Documents will be duly executed and delivered by the Company, (iv) the Transaction
Documents when executed will constitute the valid and binding obligations of the Company enforceable against the Company in accordance
with their terms, except as such enforceability may be limited by general principles of equity or applicable bankruptcy, insolvency,
reorganization, moratorium, liquidation or similar laws relating to, or affecting generally, the enforcement of creditors’
rights and remedies. 

 

    	3

    	 

    

 

		c)	Capitalization. The authorized capital stock of the Company
currently consists of 75,000,000 shares of Common Stock and no shares of preferred stock and, prior to the Merger, the authorized
capital stock of the Company will consist of 300,000,000 shares of Common Stock and 10,000,000 shares of preferred stock. As of
the date hereof, the Company has 6,190,000 shares of Common Stock issued and outstanding. All of the outstanding shares of Common
Stock and, after the Merger, of the stock of each of the Company’s Subsidiaries have been duly authorized, validly issued
and are fully paid and nonassessable. After giving effect to the Merger, and other related matters, unless otherwise indicated:
(i) except as set forth on Schedule 4c(i), no shares of capital stock of the Company
or any of its Subsidiaries will be subject to preemptive rights or any other similar rights or any liens or encumbrances suffered
or permitted by the Company; (ii) except as set forth in the PPM or on Schedule 4c(ii)
there will be no outstanding options, warrants, scrip, rights to subscribe to, calls or commitments of any character whatsoever
relating to, or securities or rights convertible into, any shares of capital stock of the Company or any of its Subsidiaries, or
contracts, commitments, understandings or arrangements by which the Company or any of its subsidiaries is or may become bound to
issue additional shares of capital stock of the Company or any of its subsidiaries, (iii) there will be no outstanding debt securities
other than indebtedness as set forth in Schedule 4c(iv), (iv) other than pursuant
to the Registration Rights Agreement or the registration rights granted pursuant to that certain Amended and Restated Investor
Rights Agreement, dated as of June [___], 2014, between Enumeral and the investor parties thereto or as set forth in Schedule
4c(v), there will be no agreements or arrangements under which the Company or any of its
Subsidiaries is obligated to register the sale of any of their securities under the Securities Act, (v) there will be no outstanding
registration statements, and there will be no outstanding comment letters from the SEC or any other regulatory agency; (vi) except
as provided in this Agreement, there will be no securities or instruments containing anti-dilution or similar provisions or as
set forth in Schedule 4c(vii), including the right to adjust the exercise, exchange
or reset price under such securities, that will be triggered by the issuance of the Units as described in this Agreement; and (vii)
no co-sale right, right of first refusal or other similar right will exist with respect to the Units (or will exist with respect
to the Warrant Shares) or the issuance and sale thereof. Immediately after giving effect to the Merger and the Closing of the Minimum
Offering or the Maximum Offering, the pro forma outstanding capitalization of the Company will be as set forth under “Pro
Forma Capitalization” in the PPM. Upon request, the Company will make available to the Subscriber true and correct copies
of the Company’s Certificate of Incorporation, and as in effect on the date hereof (the “Certificate of Incorporation”),
and the Company’s By-laws, as in effect on the date hereof (the “By-laws”), and the terms of all
securities exercisable for Common Stock and the material rights of the holders thereof in respect thereto other than stock options
issued to officers, directors, employees and consultants.

 

    	4

    	 

    

 

		d)	Issuance of Securities. The Shares and the Warrants are
duly authorized and, upon issuance in accordance with the terms hereof, shall be duly issued, fully paid and nonassessable, and
are free from all taxes, liens and charges with respect to the issue thereof. Upon issuance of the Warrant Shares upon exercise
of the Warrants, against payment therefor and in accordance with the terms of the Warrants, the Warrant Securities will be duly
issued, fully paid and nonassessable, and will be free from all taxes, liens and charges with respect to the issue thereof. 

 

		e)	No Conflicts. The execution, delivery and performance
of each of the Transaction Documents by the Company, and the consummation by the Company of the transactions contemplated hereby
and thereby will not (i) result in a violation of the Certificate of Incorporation or the By-laws (or equivalent constitutive document)
of the Company or any of its Subsidiaries or (ii) violate or conflict with, or result in a breach of any provision of, or constitute
a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of
termination, amendment, acceleration or cancellation of, any agreement, indenture or instrument to which the Company or any Subsidiary
is a party, or result in a violation of any law, rule, regulation, order, judgment or decree (including U.S. federal and state
securities laws and regulations) applicable to the Company or any Subsidiary or by which any property or asset of the Company or
any Subsidiary is bound or affected except for those which could not reasonably be expected to have a Material Adverse Effect.
Except those which could not reasonably be expected to have a Material Adverse Effect, neither the Company nor any Subsidiary is
in violation of any term of or in default under its constitutive documents. Except those which could not reasonably be expected
to have a Material Adverse Effect, neither the Company nor any Subsidiary is in violation of any term of or in default under any
material contract, agreement, mortgage, indebtedness, indenture, instrument, judgment, decree or order or any statute, rule or
regulation applicable to the Company or any Subsidiary. The business of the Company and its Subsidiaries is not being conducted,
and shall not be conducted in violation of any material law, ordinance, or regulation of any governmental entity, except for any
violation which could not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. Except as
specifically contemplated by this Agreement and as required under the Securities Act and any applicable state securities laws,
neither the Company nor any of its Subsidiaries is required to obtain any consent, authorization or order of, or make any filing
or registration with, any court or governmental agency in order for it to execute, deliver or perform any of its obligations under
or contemplated by this Agreement or the other Transaction Documents in accordance with the terms hereof or thereof. Except as
set forth on Schedule 4e, neither the execution and delivery by the Company of
the Transaction Documents, nor the consummation by the Company of the transactions contemplated hereby or thereby, will require
any notice, consent or waiver under any contract or instrument to which the Company or any Subsidiary is a party or by which the
Company or any Subsidiary is bound or to which any of their assets is subject, except for any notice, consent or waiver the absence
of which would not have a Material Adverse Effect and would not adversely affect the consummation of the transactions contemplated
hereby or thereby. All consents, authorizations, orders, filings and registrations which the Company or any of its Subsidiaries
is required to obtain pursuant to the preceding two sentences have been or will be obtained or effected on or prior to the Closing.
The Company is unaware of any facts or circumstance, which might give rise to any of the foregoing.

 

		f)	Absence of Litigation. There is no action, suit, proceeding,
inquiry or investigation before or by any court, public board, government agency, self-regulatory organization or body now pending
or, to the knowledge of the Company, threatened, against or affecting the Company or any of its Subsidiaries, wherein an unfavorable
decision, ruling or finding would (i) adversely affect the validity or enforceability of, or the authority or ability of the Company
or any of its Subsidiaries to perform its obligations under, this Agreement or any of the other Transaction Documents, or (ii)
have a Material Adverse Effect.

 

    	5

    	 

    

 

		g)	Acknowledgment Regarding Subscriber’s Purchase of the
Units. The Company acknowledges and agrees that each Subscriber is acting solely in the capacity of an arm’s length purchaser
with respect to the Transaction Documents and the transactions contemplated hereby and thereby. The Company further acknowledges
that each Subscriber is not acting as a financial advisor or fiduciary of the Company (or in any similar capacity) with respect
to the Transaction Documents and the transactions contemplated hereby and thereby and any advice given by such Subscriber or any
of their respective representatives or agents in connection with the Transaction Documents and the transactions contemplated hereby
and thereby is merely incidental to such Subscriber’s purchase of the Units (and the Warrant Shares). The Company further
represents to the Subscribers that the Company’s decision to enter into the Transaction Documents has been based solely on
the independent evaluation by the Company and its representatives.

 

		h)	No General Solicitation. Neither the Company, nor any
of its affiliates, nor, to the knowledge of the Company, any person acting on its or their behalf, has engaged in any form of general
solicitation or general advertising (within the meaning of Regulation D) in connection with the offer or sale of the Units.

 

		i)	No Integrated Offering. Neither the Company, nor any of
its affiliates, nor to the knowledge of the Company, any person acting on its or their behalf has, directly or indirectly, made
any offers or sales of any security or solicited any offers to buy any security, under circumstances that would require registration
of the Units or the securities contained therein under the Securities Act or cause this offering of the Units or the securities
contained therein to be integrated with prior offerings by the Company for purposes of the Securities Act.

 

		j)	Employee Relations. Neither Company nor any Subsidiary
is involved in any labor dispute nor, to the knowledge of the Company, is any such dispute threatened. Neither Company nor any
Subsidiary is party to any collective bargaining agreement. The Company’s and/or its Subsidiaries’ employees are not
members of any union, and the Company believes that its and its Subsidiaries’ relationship with their respective employees
is good.

 

		k)	Intellectual Property Rights. After giving effect to the
Merger, and other related matters, unless otherwise indicated, except as set forth on Schedule 4k,
to the knowledge of the Company, the Company and its Subsidiaries own or possess all patents, trademarks, domain names (whether
or not registered) and any patentable improvements or copyrightable derivative works thereof, websites and intellectual property
rights relating thereto, service marks, trade names, copyrights, licenses and authorizations, and all rights with respect to the
foregoing, which are necessary for the conduct of its business as now conducted without any conflict with the rights of others
except for such conflicts that would not result in a Material Adverse Effect. Neither Company nor any Subsidiary has received any
notice of infringement of, or conflict with, the asserted rights of others with respect to any intellectual property that it utilizes.

 

    	6

    	 

    

  

		l)	Environmental Laws.

 

		(i)	The Company and each Subsidiary has complied with all applicable Environmental Laws (as defined
below), except for violations of Environmental Laws that, individually or in the aggregate, have not had and would not reasonably
be expected to have a Material Adverse Effect. There is no pending or, to the knowledge of the Company, threatened civil or criminal
litigation, written notice of violation, formal administrative proceeding, or investigation, inquiry or information request, relating
to any Environmental Law involving the Company or any Subsidiary, except for litigation, notices of violations, formal administrative
proceedings or investigations, inquiries or information requests that, individually or in the aggregate, have not had and would
not reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, “Environmental Law” means
any national, state, provincial or local law, statute, rule or regulation or the common law relating to the environment or occupational
health and safety, including without limitation any statute, regulation, administrative decision or order pertaining to (i) treatment,
storage, disposal, generation and transportation of industrial, toxic or hazardous materials or substances or solid or hazardous
waste; (ii) air, water and noise pollution; (iii) groundwater and soil contamination; (iv) the release or threatened release into
the environment of industrial, toxic or hazardous materials or substances, or solid or hazardous waste, including without limitation
emissions, discharges, injections, spills, escapes or dumping of pollutants, contaminants or chemicals; (v) the protection of wild
life, marine life and wetlands, including without limitation all endangered and threatened species; (vi) storage tanks, vessels,
containers, abandoned or discarded barrels, and other closed receptacles; (vii) health and safety of employees and other persons;
and (viii) manufacturing, processing, using, distributing, treating, storing, disposing, transporting or handling of materials
regulated under any law as pollutants, contaminants, toxic or hazardous materials or substances or oil or petroleum products or
solid or hazardous waste. As used above, the terms “release” and “environment” shall have the meaning set
forth in the Comprehensive Environmental Response, Compensation and Liability Act of 1980, as amended.

 

		(ii)	To the knowledge of the Company there is no material environmental liability with respect to any
solid or hazardous waste transporter or treatment, storage or disposal facility that has been used by the Company or any Subsidiary.

 

		(iii)	The Company and its Subsidiaries (i) have received all permits, licenses or other approvals required
of them under applicable Environmental Laws to conduct their respective businesses and (ii) are in compliance, in all material
respects, with all terms and conditions of any such permit, license or approval.

 

    	7

    	 

    

 

		m)	Permits; FDA Compliance. The Company and its Subsidiaries
have all authorizations, approvals, clearances, licenses, permits, certificates or exemptions (including manufacturing approvals
and authorizations, pricing and reimbursement approvals, labeling approvals, registration notifications or their foreign equivalent)
issued by any regulatory authority or governmental agency (collectively, “Permits”) required to conduct
their respective businesses as currently conducted except to the extent that the failure to have such Permits would not have a
Material Adverse Effect. The conduct of business by the Company complies, and at all times has substantially complied, in all material
respects with the Federal Food, Drug and Cosmetic Act (the “FDCA”) and similar federal, state and foreign
laws applicable to the evaluation, testing, manufacturing, distribution, advertising and marketing of each of the Company’s
products, in whatever stage of development or commercialization except to the extent that the failure to so comply would not have
a Material Adverse Effect. To the knowledge of the Company, as of the date hereof, neither the United States Food and Drug Administration
(the “FDA”) nor any comparable regulatory authority or governmental agency is considering limiting, suspending
or revoking any such Permit or changing the marketing classification or labeling of the products of the Company or any of its Subsidiaries.
To the knowledge of the Company, there is no false or misleading information or material omission in any product application or
other submission by the Company or any of its Subsidiaries to the FDA or any comparable regulatory authority or governmental agency.
The Company or its Subsidiaries have fulfilled and performed in all material respects their obligations under each Permit, and,
as of the date hereof, to the knowledge of the Company, no event has occurred or condition or state of facts exists which would
constitute a breach or default or would cause revocation or termination of any such Permit except to the extent that such breach,
default, revocation or termination would not have a Material Adverse Effect. To the knowledge of the Company, any third party that
is a manufacturer or contractor for the Company or any of its Subsidiaries is in compliance in all material respects with all Permits
insofar as they pertain to the manufacture of product components or products for the Company. The Company and its Subsidiaries
have not received any Form FDA-483, notice of adverse finding, FDA warning letter, notice of violation or “untitled letter,”
notice of FDA action for import detention or refusal, or any other notice from the FDA or other governmental agency alleging or
asserting noncompliance with any applicable laws or Permits. The Company and its Subsidiaries are not subject to any obligation
arising under an administrative or regulatory action, FDA inspection, FDA warning letter, FDA notice of violation letter or other
notice, response or commitment made to or with the FDA or any comparable regulatory authority or governmental agency. The Company
and its Subsidiaries have made all notifications, submissions and reports required by the FDCA or similar federal, state and foreign
laws, except to the extent that the failure to make such notifications, submission or reports would not have a Material Adverse
Effect.

 

		n)	Title. After giving effect to the Merger, and other related
matters, unless otherwise indicated, neither the Company nor any of its Subsidiaries owns
any real property. After giving effect to the Merger, and other related matters, unless otherwise indicated, except as set forth
on Schedule 4n, each of the Company and its Subsidiaries has good and marketable
title to all of its personal property and assets, free and clear of any material restriction, mortgage, deed of trust, pledge,
lien, security interest or other charge, claim or encumbrance which would have a Material Adverse Effect. After giving effect to
the Merger, and other related matters, unless otherwise indicated, except as set forth on Schedule 4n,
with respect to properties and assets it leases, each of the Company and its Subsidiaries is in material compliance with such leases
and holds a valid leasehold interest free of any liens, claims or encumbrances which would have a Material Adverse Effect. 

 

		o)	No Material Adverse Breaches, etc. Neither Company nor
any Subsidiary is subject to any charter, corporate or other legal restriction, or any judgment, decree, order, rule or regulation
which in the judgment of the Company’s officers has had, or is reasonably expected in the future to have, a Material Adverse
Effect. Neither Company nor any Subsidiary is in breach of any contract or agreement which breach, in the judgment of the Company’s
officers, has had, or is reasonably expected to have a Material Adverse Effect.

 

    	8

    	 

    

 

		p)	Tax Status. The Company and each Subsidiary has made and
filed (taking into account any valid extensions) all federal and state income and all other tax returns, reports and declarations
required by any jurisdiction to which it is subject and (unless and only to the extent that the Company or such Subsidiary has
set aside on its books provisions reasonably adequate for the payment of all unpaid and unreported taxes) has paid all taxes and
other governmental assessments and charges that are material in amount, shown or determined to be due on such returns, reports
and declarations, except those being contested in good faith and has set aside on its books provision reasonably adequate for the
payment of all taxes for periods subsequent to the periods to which such returns, reports or declarations apply. To the knowledge
of the Company, there are no unpaid taxes in any material amount claimed to be due from the Company or any Subsidiary by the taxing
authority of any jurisdiction, and the officers of the Company know of no basis for any such claim.

 

		q)	Certain Transactions. Except for arm’s length transactions
pursuant to which the Company or any Subsidiary makes payments in the ordinary course of business upon terms no less favorable
than it could obtain from third parties, none of the officers, directors, or employees of the Company or any Subsidiary is presently
a party to any transaction with the Company or any Subsidiary (other than for services as employees, officers and directors), including
any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or
personal property to or from, or otherwise requiring payments to or from any officer, director or such employee or, to the knowledge
of the Company, any corporation, partnership, trust or other entity in which any officer, director, or any such employee has a
substantial interest or is an officer, director, trustee or partner.

 

		r)	Rights of First Refusal. After giving effect to the Merger,
and other related matters, unless otherwise indicated, except as set forth on Schedule 4c(i)
or Schedule 4r, the Company is not obligated to offer the securities offered hereunder
on a right of first refusal basis or otherwise to any third parties including, but not limited to, current or former stockholders
of the Company, underwriters, brokers, agents or other third parties.

 

		s)	Reliance. The Company acknowledges that the Subscriber
is relying on the representations and warranties made by the Company hereunder and that such representations and warranties are
a material inducement to the Subscriber purchasing the Units. The Company further acknowledges that without such representations
and warranties of the Company made hereunder, the Subscribers would not enter into this Agreement.

 

		t.	Brokers’ Fees. Except as set forth in the PPM or on Schedule 4t, the
Company does not have any liability or obligation to pay any fees or commissions to any broker, finder or agent with respect to
the transactions contemplated by this Agreement, except for the payment of fees to the Placement Agent as described below

 

		u.	SEC Reports. The Company has filed all reports, schedules, forms, statements and other documents
required to be filed by the Company under the Securities Exchange Act of 1934, as amended, including pursuant to Section 13(a)
or 15(d) thereof, for the two years preceding the date hereof (or such shorter period as the Company was required by law or regulation
to file such material).

 

    	9

    	 

    

 

		5.	Representations, Warranties and Agreements of the Subscriber. The Subscriber represents
and warrants to, and agrees with, the Company the following:

 

		a.	The Subscriber, its advisers, if any, and its designated representatives, if any, have the knowledge
and experience in financial and business matters necessary to evaluate the merits and risks of its prospective investment in the
Company, and have carefully reviewed and understand the risks of, and other considerations relating to, the purchase of Units and
the tax consequences of the investment, and have the ability to bear the economic risks of the investment.

 

		b.	The Subscriber is acquiring the Units, and upon exercise of the Warrants, the Warrant Shares, for
investment for its own account and not with the view to, or for resale in connection with, any distribution thereof. The Subscriber
understands and acknowledges that the Units, the Shares and the Warrants have not been, and the Warrant Shares will not be, registered
under the Securities Act or any state securities laws, by reason of a specific exemption from the registration provisions of the
Securities Act and applicable state securities laws, which depends upon, among other things, the bona fide nature of the investment
intent as expressed herein. The Subscriber further represents that it does not have any contract, undertaking, agreement or arrangement
with any person to sell, transfer or grant participation to any third person with respect to any of the Units, the Shares, the
Warrants or the Warrant Shares. The Subscriber understands and acknowledges that the offering of the Units pursuant to this Agreement
will not be registered under the Securities Act nor under the state securities laws on the ground that the sale provided for in
this Agreement and the issuance of securities hereunder is exempt from the registration requirements of the Securities Act and
any applicable state securities laws.

 

		c.	The Subscriber is an “accredited investor” as defined in Rule 501 of Regulation D as
promulgated by the Securities and Exchange Commission under the Securities Act, for the reason(s) specified on the Accredited
Investor Certification attached hereto as completed by Subscriber, and Subscriber shall submit to the Company such further
assurances of such status as may be reasonably requested by the Company. The Subscriber further acknowledges and understands that
it is required to be an “accredited investor” at the time it exercises the Warrants. The Subscriber resides in the
jurisdiction set forth on the Subscriber’s Omnibus Signature Page affixed hereto.

 

		d.	The Subscriber (i) if a natural person, represents that he or she is the greater of (A) 21 years
of age or (B) the age of legal majority in his or her jurisdiction of residence, and has full power and authority to execute and
deliver this Agreement and all other related agreements or certificates and to carry out the provisions hereof and thereof; (ii)
if a corporation, partnership, or limited liability company or partnership, or association, joint stock company, trust, unincorporated
organization or other entity, represents that such entity was not formed for the specific purpose of acquiring the Units, such
entity is duly organized, validly existing and in good standing under the laws of the state or jurisdiction of its organization,
the consummation of the transactions contemplated hereby is authorized by, and will not result in a violation of state law or its
charter or other organizational documents, such entity has full power and authority to execute and deliver this Agreement and all
other related agreements or certificates and to carry out the provisions hereof and thereof and to purchase and hold the Units,
the execution and delivery of this Agreement has been duly authorized by all necessary action, this Agreement has been duly executed
and delivered on behalf of such entity and is a legal, valid and binding obligation of such entity; or (iii) if executing this
Agreement in a representative or fiduciary capacity, represents that it has full power and authority to execute and deliver this
Agreement in such capacity and on behalf of the subscribing individual, ward, partnership, trust, estate, corporation, or limited
liability company or partnership, or other entity for whom the Subscriber is executing this Agreement, and such individual, partnership,
ward, trust, estate, corporation, or limited liability company or partnership, or other entity has full right and power to perform
pursuant to this Agreement and make an investment in the Company, and represents that this Agreement constitutes a legal, valid
and binding obligation of such entity. The execution and delivery of this Agreement will not violate or be in conflict with any
order, judgment, injunction, agreement or controlling document to which the Subscriber is a party or by which it is bound.

 

    	10

    	 

    

 

		e.	The Subscriber understands that the Units are being offered and sold to it in reliance on specific
exemptions from the registration requirements of United States federal and state securities laws and that the Company is relying
in part upon the truth and accuracy of, and such Subscriber’s compliance with, the representations, warranties, agreements,
acknowledgments and understandings of such Subscriber set forth herein in order to determine the availability of such exemptions
and the eligibility of such Subscriber to acquire such securities. The Subscriber further acknowledges and understands that the
Company is relying on the representations and warranties made by the Subscriber hereunder and that such representations and warranties
are a material inducement to the Company to sell the Units to the Subscriber. The Subscriber further acknowledges that without
such representations and warranties of the Subscriber made hereunder, the Company would not enter into this Agreement with the
Subscriber.

 

		f.	The Subscriber understands that no public market now exists, and there never will be a public market
for, the Units or the Warrants, that only a limited public market for the Company’s Common Stock exists and that there can
be no assurance that an active public market for the Common Stock will exist or continue to exist.

 

		g.	The Subscriber, its advisers, if any, and its designated representatives, if any, have received
and reviewed information about the Company, including all Disclosure Materials, and have had an opportunity to discuss the Company’s
business, management and financial affairs with the Company’s management. The Subscriber understands that such discussions,
as well as any Disclosure Material provided by the Company, were intended to describe the aspects of the Company’s business
and prospects which the Company believes to be material, but were not necessarily a thorough or exhaustive description, and except
as expressly set forth in this Agreement, the Company makes no representation or warranty with respect to the completeness of such
information and makes no representation or warranty of any kind with respect to any information provided by any entity other than
the Company. Some of such information may include projections as to the future performance of the Company, which projections may
not be realized, may be based on assumptions which may not be correct and may be subject to numerous factors beyond the Company’s
control. Additionally, the Subscriber understands and represents that it is purchasing the Units notwithstanding the fact that
the Company may disclose in the future certain material information the Subscriber has not received, including (without limitation)
financial statements of the Company and/or Enumeral for the current or prior fiscal periods, and any subsequent period financial
statements that will be filed with the Securities and Exchange Commission, that it is not relying on any such information in connection
with its purchase of the Units and that it waives any right of action with respect to the nondisclosure to it prior to its purchase
of the Units of any such information. Each Subscriber has sought such accounting, legal and tax advice as it has considered necessary
to make an informed investment decision with respect to its acquisition of the Units.

 

    	11

    	 

    

 

		h.	The Subscriber acknowledges that the Company is not acting as a financial advisor or fiduciary
of the Subscriber (or in any similar capacity) with respect to the Transaction Documents and the transactions contemplated hereby
and thereby and no investment advice has been given by the Company or any of its representatives or agents in connection with the
Transaction Documents and the transactions contemplated hereby and thereby. The Subscriber further represents to the Company that
the Subscriber’s decision to enter into the Transaction Documents has been based solely on the independent evaluation by
the Subscriber and its representatives.

 

		i.	As of the Closing, all actions on the part of Subscriber, and its officers, directors and partners,
if applicable, necessary for the authorization, execution and delivery of this Agreement, the Registration Rights Agreement and
the Voting Agreement and the performance of all obligations of the Subscriber hereunder and thereunder shall have been taken, and
this Agreement, the Registration Rights Agreement and the Voting Agreement, assuming due execution by the parties hereto and thereto,
constitute valid and legally binding obligations of the Subscriber, enforceable in accordance with their respective terms, subject
to: (i) judicial principles limiting the availability of specific performance, injunctive relief, and other equitable remedies
and (ii) bankruptcy, insolvency, reorganization, moratorium or other similar laws now or hereafter in effect generally relating
to or affecting creditors’ rights.

 

		j.	Subscriber represents that neither it nor, to its knowledge, any person or entity controlling,
controlled by or under common control with it, nor any person having a beneficial interest in it, nor any person on whose behalf
the Subscriber is acting: (i) is a person listed in the Annex to Executive Order No. 13224 (2001) issued by the President of the
United States (Executive Order Blocking Property and Prohibiting Transactions with Persons Who Commit, Threaten to Commit, or Support
Terrorism); (ii) is named on the List of Specially Designated Nationals and Blocked Persons maintained by the U.S. Office of Foreign
Assets Control; (iii) is a non-U.S. shell bank or is providing banking services indirectly to a non-U.S. shell bank; (iv) is a
senior non-U.S. political figure or an immediate family member or close associate of such figure; or (v) is otherwise prohibited
from investing in the Company pursuant to applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations,
rules or orders (categories (i) through (v), each a “Prohibited Subscriber”). The Subscriber agrees to
provide the Company, promptly upon request, all information that the Company reasonably deems necessary or appropriate to comply
with applicable U.S. anti-money laundering, anti-terrorist and asset control laws, regulations, rules and orders. The Subscriber
consents to the disclosure to U.S. regulators and law enforcement authorities by the Company and its affiliates and agents of such
information about the Subscriber as the Company reasonably deems necessary or appropriate to comply with applicable U.S. antimony
laundering, anti-terrorist and asset control laws, regulations, rules and orders. If the Subscriber is a financial institution
that is subject to the USA Patriot Act, the Subscriber represents that it has met all of its obligations under the USA Patriot
Act. The Subscriber acknowledges that if, following its investment in the Company, the Company reasonably believes that the Subscriber
is a Prohibited Subscriber or is otherwise engaged in suspicious activity or refuses to promptly provide information that the Company
requests, the Company has the right or may be obligated to prohibit additional investments, segregate the assets constituting the
investment in accordance with applicable regulations or immediately require the Subscriber to transfer the Shares, Warrants and/or
the Warrant Shares. The Subscriber further acknowledges that the Subscriber will have no claim against the Company or any of its
affiliates or agents for any form of damages as a result of any of the foregoing actions.

 

    	12

    	 

    

 

If the Subscriber is affiliated
with a non-U.S. banking institution (a “Foreign Bank”), or if the Subscriber receives deposits from,
makes payments on behalf of, or handles other financial transactions related to a Foreign Bank, the Subscriber represents and warrants
to the Company that: (1) the Foreign Bank has a fixed address, other than solely an electronic address, in a country in which the
Foreign Bank is authorized to conduct banking activities; (2) the Foreign Bank maintains operating records related to its banking
activities; (3) the Foreign Bank is subject to inspection by the banking authority that licensed the Foreign Bank to conduct banking
activities; and (4) the Foreign Bank does not provide banking services to any other Foreign Bank that does not have a physical
presence in any country and that is not a regulated affiliate.

 

		k.	The Subscriber or its duly authorized representative realizes that because of the inherently speculative
nature of businesses of the kind conducted and contemplated by the Company, the Company’s financial results may be expected
to fluctuate from month to month and from period to period and will, generally, involve a high degree of financial and market risk
that could result in substantial or, at times, even total losses for investors in securities of the Company.

 

		l.	The Subscriber has adequate means of providing for its current and anticipated financial needs
and contingencies, is able to bear the economic risk for an indefinite period of time and has no need for liquidity of the investment
in the Units and could afford complete loss of such investment.

 

		m.	The Subscriber is not subscribing for Units as a result of or subsequent to any advertisement,
article, notice or other communication, published in any newspaper, magazine or similar media or broadcast over television, radio,
or the internet, or presented at any seminar or meeting, or any solicitation of a subscription by a person not previously known
to the Subscriber in connection with investments in securities generally.

 

		n.	The Subscriber acknowledges that no U.S. federal or state agency or any other government or governmental
agency has passed upon the Units, the Shares, the Warrants or the Warrant Shares or made any finding or determination as to the
fairness, suitability or wisdom of any investments therein.

 

		o.	The Subscriber agrees to be bound by all of the terms and conditions of the Registration Rights
Agreement and the Voting Agreement and to perform all obligations thereby imposed upon it.

 

		p.	All of the information that the Subscriber has heretofore furnished or which is set forth herein
is true, correct and complete as of the date of this Agreement, and, if there should be any material change in such information
prior to the admission of the undersigned to the Company, the Subscriber will immediately furnish revised or corrected information
to the Company.

 

		q.	(For ERISA plans only) The fiduciary of the ERISA plan (the “Plan”)
represents that such fiduciary has been informed of and understands the Company’s investment objectives, policies and strategies,
and that the decision to invest “plan assets” (as such term is defined in ERISA) in the Company is consistent with
the provisions of ERISA that require diversification of plan assets and impose other fiduciary responsibilities. The Subscriber
fiduciary or Plan (a) is responsible for the decision to invest in the Company; (b) is independent of the Company or any of its
affiliates; (c) is qualified to make such investment decision; and (d) in making such decision, the Purchaser fiduciary or Plan
has not relied primarily on any advice or recommendation of the Company or any of its affiliates.

 

    	13

    	 

    

 

		6.	Transfer Restrictions. The Subscriber acknowledges and agrees as follows:

 

		a.	The Units, the Shares, the Warrants and the Warrant Shares have not been registered for sale under
the Securities Act, in reliance on the private offering exemption in Section 4(a)(2) thereof; other than as expressly provide in
the Registration Rights Agreement, the Company does not currently intend to register the Units, the Shares, the Warrants or the
Warrant Shares under the Securities Act at any time in the future; and the undersigned will not immediately be entitled to the
benefits of Rule 144 with respect to the Units, the Shares, the Warrants and the Warrant Shares.

 

		b.	The Subscriber understands that there are substantial restrictions on the transferability of the
Shares, the Warrants and the Warrant Shares (collectively, the “Securities”) that the certificates representing
the Securities shall bear a restrictive legend in substantially the following form (or in the case of the Warrants, as shown on
the form of Warrant attached hereto) (and a stop-transfer order may be placed against transfer of such certificates or other instruments):

 

THE
SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES
ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED,
ASSIGNED OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT
AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION
OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY
BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OR APPLICABLE STATE SECURITIES LAWS. HEDGING
TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

 

The legend set
forth above shall be removed and the Company shall issue a certificate without such legend to the holder of the Securities upon
which it is stamped, if (a) such Shares are sold pursuant to a registration statement under the Securities Act, or (b) such
holder delivers to the Company an opinion of counsel, reasonably acceptable to the Company, that a disposition of the Securities
is being made pursuant to an exemption from such registration and that the Securities, after such transfer, shall no longer be
“restricted securities” within the meaning of Rule 144.

 

		c.	Each Subscriber understands that prior to the Merger, the Company will be a “shell company”
as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
and that upon the filing of a Current Report on Form 8-K (the “Super 8-K) reporting the consummation of the Merger and the
Transactions and otherwise containing Form 10 information discussed below, the Company will cease to be a shell company. Pursuant
to Rule 144(i), securities issued by a current or former shell company (that is, the Securities) that otherwise meet the holding
period and other requirements of Rule 144 nevertheless cannot be sold in reliance on Rule 144 until one year after the Company
(a) is no longer a shell company; and (b) has filed current “Form 10 information“ (as defined in Rule 144(i)) with
the SEC reflecting that it is no longer a shell company, and provided that at the time of a proposed sale pursuant to Rule 144,
the Company is subject to the reporting requirements of Section 13 or 15(d) of the Exchange Act and has filed all reports and other
materials required to be filed by Section 13 or 15(d) of the Exchange Act, as applicable, during the preceding 12 months (or for
such shorter period that the issuer was required to file such reports and materials), other than Form 8-K reports. As a result,
the restrictive legends on certificates for the Securities cannot be removed except in connection with an actual sale meeting the
foregoing requirements or pursuant to an effective registration statement.

 

    	14

    	 

    

 

		7.	Indemnification. The Subscriber agrees to indemnify and hold harmless the Company, the Placement
Agent and any other broker, agent or finder engaged by the Company for the Offering, and their respective officers, directors,
employees, agents, control persons and affiliates from and against all losses, liabilities, claims, damages, costs, fees and expenses
whatsoever (including, but not limited to, any and all expenses incurred in investigating, preparing or defending against any litigation
commenced or threatened) based upon or arising out of the Subscriber’s actual or alleged false acknowledgment, representation
or warranty, or misrepresentation or omission to state a material fact, or breach by the Subscriber of any covenant or agreement
made by the Subscriber, contained herein or in any other document delivered by the Subscriber in connection with this Agreement.

 

		8.	Revocability; Binding Effect. The subscription hereunder may be revoked prior to the Closing
thereon, provided that written notice of revocation is sent and is received by the Company or either of the Placement Agent at
least two business days prior to the Closing on such subscription. The Subscriber hereby acknowledges and agrees that this Agreement
shall survive the death or disability of the Subscriber and shall be binding upon and inure to the benefit of the parties and their
heirs, executors, administrators, successors, legal representatives and permitted assigns. If the Subscriber is more than one person,
the obligations of the Subscriber hereunder shall be joint and several and the agreements, representations, warranties and acknowledgments
herein shall be deemed to be made by and be binding upon each such person and such person’s heirs, executors, administrators,
successors, legal representatives and permitted assigns.

 

		9.	Modification. This Agreement shall not be modified or waived except by an instrument in
writing signed by the party against whom any such modification or waiver is sought to be enforced.

 

		10.	Immaterial Modifications to the Registration Rights Agreement and the Voting Agreement.
The Company may, at any time prior to the initial Closing, amend the Registration Rights Agreement and the Voting Agreement if
necessary to clarify any provision therein, without first providing notice or obtaining prior consent of the Subscriber.

 

11.     Notices.
Any notice or other communication required or permitted to be given hereunder shall be in writing and shall be mailed by certified
mail, return receipt requested, or delivered against receipt to the party to whom it is to be given (a) if to the Company, at the
address set forth above, with a copy to Crone Kline
Rinde LLP, 488 Madison Ave., 12th Fl., New York, NY 10022, Attention: Brian S. DiPaolo,
Esq., facsimile +1-212-400-6901 and Duane Morris, LLP., 100 High Street, Suite 2400, Boston, MA 02110-1724, Attention Jonathan
Lourie, Esq., facsimile +1-857-401-3089 or (b) if to the Subscriber, at the address set forth on the Omnibus Signature Page hereof
(or, in either case, to such other address as the party shall have furnished in writing in accordance with the provisions of this
Section). Any notice or other communication given by certified mail shall be deemed given at the time of certification thereof,
except for a notice changing a party’s address which shall be deemed given at the time of receipt thereof.

 

    	15

    	 

    

 

		12.	Assignability. This Agreement and the rights, interests and obligations hereunder are not
transferable or assignable by the Subscriber, and the transfer or assignment of the Units, the Shares, the Warrants or the Warrant
Shares shall be made only in accordance with all applicable laws.

 

		13.	Applicable Law. This Agreement shall be governed by and construed in accordance with the
laws of the State of New York, without reference to the principles thereof relating to the conflict of laws.

 

		14.	Arbitration. The parties agree to submit all controversies to arbitration in accordance
with the provisions set forth below and understand that:

 

		a.	Arbitration shall be final and binding on the parties.

 

		b.	The parties are waiving their right to seek remedies in court, including the right to a jury trial.

 

		c.	Pre-arbitration discovery is generally more limited and different from court proceedings.

 

		d.	The arbitrator’s award is not required to include factual findings or legal reasoning and
any party’s right to appeal or to seek modification of rulings by arbitrators is strictly limited.

 

		e.	The panel of arbitrators will typically include a minority of arbitrators who were or are affiliated
with the securities industry.

 

		f.	All controversies which may arise between the parties concerning this Agreement shall be determined
by arbitration pursuant to the rules then pertaining to the Financial Industry Regulatory Authority in New York City, New York.
Judgment on any award of any such arbitration may be entered in the Supreme Court of the State of New York or in any other court
having jurisdiction of the person or persons against whom such award is rendered. Any notice of such arbitration or for the confirmation
of any award in any arbitration shall be sufficient if given in accordance with the provisions of this Agreement. The parties agree
that the determination of the arbitrators shall be binding and conclusive upon them. The prevailing party, as determined by such
arbitrators, in a legal proceeding shall be entitled to collect any costs, disbursements and reasonable attorney’s fees from
the other party. Prior to filing an arbitration, the parties hereby agree that they will attempt to resolve their differences first
by submitting the matter for resolution to a mediator, acceptable to all parties, and whose expenses will be borne equally by all
parties. The mediation will be held in the County of New York, State of New York, on an expedited basis. If the parties cannot
successfully resolve their differences through mediation, the matter will be resolved by arbitration. The arbitration shall take
place in the County of New York, State of New York, on an expedited basis.

 

    	16

    	 

    

 

		15.	Blue Sky Qualification. The purchase of Units under this Agreement is expressly conditioned
upon the exemption from qualification of the offer and sale of the Units from applicable federal and state securities laws. The
Company shall not be required to qualify this transaction under the securities laws of any jurisdiction and, should qualification
be necessary, the Company shall be released from any and all obligations to maintain its offer, and may rescind any sale contracted,
in the jurisdiction.

 

		16.	Use of Pronouns. All pronouns and any variations thereof used herein shall be deemed to
refer to the masculine, feminine, neuter, singular or plural as the identity of the person or persons referred to may require.

 

		17.	Confidentiality. The Subscriber acknowledges and agrees that any information or data the
Subscriber has acquired from or about the Company or may acquire in the future, not otherwise properly in the public domain, including,
without limitation, the Disclosure Materials, was received in confidence. The Subscriber agrees not to divulge, communicate or
disclose, except as may be required by law or for the performance of this Agreement, or use to the detriment of the Company or
for the benefit of any other person, or misuse in any way, any confidential information of the Company, including any scientific,
technical, trade or business secrets of the Company and any scientific, technical, trade or business materials that are treated
by the Company as confidential or proprietary, including, but not limited to, internal personnel and financial information of the
Company or its affiliates, the manner and methods of conducting the business of the Company or its affiliates and confidential
information obtained by or given to the Company about or belonging to third parties. The Subscriber understands that the Company
may rely on Subscriber’s agreement of confidentiality to comply with the exemptive provisions of Regulation FD under the
Securities Act of 1933 as set forth in Rule 100(a)(b)(2)(ii) of Regulation FD. In addition, the Subscriber acknowledges that it
is aware that the United States securities laws generally prohibit any person who is in possession of material nonpublic information
about a public company such as the Company from purchasing or selling securities of such company. The provisions of this Section
17 are in addition to and not in replacement of any other confidentiality agreement between the Company and the Subscriber.

 

		18.	Anti-Dilution. The Shares shall
                                         have anti-dilution protection such that if within twenty-four (24) months after the final
                                         Closing of the Offering the Company shall issue Additional Shares of Common Stock (as
                                         defined below) without consideration or for a consideration per share, or with an exercise
                                         or conversion price per share, less than the Purchase Price, the Subscriber shall be
                                         entitled to receive from the Company (for no additional consideration) additional Shares
                                         in an amount such that, when added to the number of Shares purchased by Subscriber under
                                         this Agreement, will equal the number of Shares that the Subscriber’s Purchase
                                         Price for the Shares set forth on the Subscriber’s signature page hereof would
                                         have purchased at the Adjusted Price (as defined below). The “Adjusted Price”
                                         shall be a price (calculated to the nearest cent) determined by multiplying the Adjusted
                                         Price per share in effect immediately prior to such issue (which, for avoidance of doubt,
                                         shall be $1.00 prior to the first such issue)1 by a fraction, (A) the
                                         numerator of which shall be (1) the number of shares of Common Stock outstanding immediately
                                         prior to such issue plus (2) the number of shares of Common Stock which the aggregate
                                         consideration received or to be received by the Company for the total number of Additional
                                         Shares of Common Stock so issued would purchase at such Adjusted Price; and (B) the denominator
                                         of which shall be (1) the number of shares of Common Stock outstanding immediately prior
                                         to such issue plus (2) the number of such Additional Shares of Common Stock so issued;
                                         provided that, (i) for the purpose of this Section, all shares of Common Stock
                                         issuable upon conversion or exchange of convertible securities outstanding immediately
                                         prior to such issue shall be deemed to be outstanding, and (ii) the number of shares
                                         of Common Stock deemed issuable upon conversion or exchange of such outstanding convertible
                                         securities shall be determined without giving effect to any adjustments to the conversion
                                         or exchange price or conversion or exchange rate of such convertible securities resulting
                                         from the issuance of Additional Shares of Common Stock that is the subject of this calculation.

 

    	17

    	 

    

 

“Additional
Shares of Common Stock” shall mean all shares of Common Stock issued by the Company after the first Closing of the
Offering (including without limitation any shares of Common Stock issuable upon conversion or exchange of any convertible securities
or upon exercise of any option or warrant, on an as-converted basis), other than: (i) shares of Common Stock issued or issuable
upon conversion or exchange of any convertible securities or exercise of any options or warrants outstanding as of immediately
following the Merger and the initial Closing; (ii) shares of Common Stock issued or issuable upon exercise of the Warrants or
the Placement Agent Warrants; (iii) shares of Common Stock issued or issuable by reason of a dividend, stock split, split-up or
other distribution on shares of Common Stock relating to any recapitalization, reclassification or reorganization of the capital
stock of the Company, or any consolidation or merger of the Company with another corporation, or the sale of all or substantially
all of its assets or other transaction effected in such a way that there is no change of control; (iv) shares of Common Stock
issued in a firmly underwritten registered public offering under the Securities Act; (v) shares of Common Stock issued or issuable
pursuant to the acquisition of another entity or business by the Company by merger, purchase of substantially all of the assets
or other reorganization or pursuant to a joint venture or technology license agreement, but not including a transaction in which
the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business is investing
in securities; (vi) shares of Common Stock issued or issuable to officers, directors and employees of, or consultants to,
the Company pursuant to stock grants, option plans, purchase plans or other employee stock incentive programs or arrangements
approved by the Board of Directors, or upon exercise of options or warrants granted to such parties pursuant to any such plan
or arrangement; (vii) any securities issued or issuable by the Company pursuant to the Subscription Agreements; and (viii) securities
issued to financial institutions, institutional investors or lessors in connection with credit arrangements, equipment financings,
lease arrangements or similar transactions, in the aggregate not exceeding ten percent (10%) of the number of shares of Common
Stock outstanding at any time, and in case of clauses (iii) through (viii) above, such issuance is approved by a majority of disinterested
directors of the Company and includes no “death spiral” provision of any kind. 

 

		19.	Miscellaneous.

 

		a.	This Agreement, together with the Registration Rights Agreement, the Voting Agreement the Warrant
and any Confidentiality Agreement, constitute the entire agreement between the Subscriber and the Company with respect to the Offering
and supersede all prior oral or written agreements and understandings, if any, relating to the subject matter hereof. The terms
and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by a written document executed
by the party entitled to the benefits of such terms or provisions.

 

		b.	The representations and warranties of the Company and the Subscriber made in this Agreement shall
survive the execution and delivery hereof and delivery of the Common Stock and the Warrants contained in the Units
for a period of twelve (12) months following the Closing Date.

 

    	18

    	 

    

 

		c.	Each of the parties hereto shall pay its own fees and expenses (including the fees of any attorneys,
accountants, appraisers or others engaged by such party) in connection with this Agreement and the transactions contemplated hereby,
whether or not the transactions contemplated hereby are consummated.

 

		d.	This Agreement may be executed in one or more original or facsimile counterparts, each of which
shall be deemed an original, but all of which shall together constitute one and the same instrument and which shall be enforceable
against the parties actually executing such counterparts. The exchange of copies of this Agreement and of signature pages by facsimile
transmission or in .pdf format shall constitute effective execution and delivery of this Agreement as to the parties and may be
used in lieu of the original Agreement for all purposes. Signatures of the parties transmitted by facsimile or in pdf format shall
be deemed to be their original signatures for all purposes.

 

		e.	Each provision of this Agreement shall be considered separable and, if for any reason any provision
or provisions hereof are determined to be invalid or contrary to applicable law, such invalidity or illegality shall not impair
the operation of or affect the remaining portions of this Agreement.

 

		f.	Paragraph titles are for descriptive purposes only and shall not control or alter the meaning of
this Agreement as set forth in the text.

 

		g.	The Subscriber understands and acknowledges that there may be multiple Closings for the Offering.

 

		h.	The Subscriber hereby agrees to furnish the Company such other information as the Company may request
prior to the Closing with respect to its subscription hereunder.

 

		20.	Omnibus Signature Page. This Agreement is intended to be read and construed in conjunction
with the Registration Rights Agreement and the Voting Agreement. Accordingly, pursuant to the terms and conditions of this Agreement
the Registration Rights Agreement and the Voting Agreement, it is hereby agreed that the execution by the Subscriber of this Agreement,
in the place set forth on the Omnibus Signature Page below, shall constitute agreement to be bound by the terms and conditions
hereof and the terms and conditions of the Registration Rights Agreement and the Voting Agreement, with the same effect as if each
of such separate but related agreement were separately signed.

 

		21.	Public Disclosure. Neither the Subscriber nor any officer, manager, director, member, partner,
stockholder, employee, affiliate, affiliated person or entity of the Subscriber shall make or issue any press releases or otherwise
make any public statements or make any disclosures to any third person or entity with respect to the transactions contemplated
herein and will not make or issue any press releases or otherwise make any public statements of any nature whatsoever with respect
to the Company without the Company’s express prior approval. The Company has the right to withhold such approval in its sole
discretion.

 

		22.	Potential Conflicts.

 

EDI Financial, Inc., a Placement Agent and/or
their respective affiliates, principals, representatives or employees may now or hereafter own shares of the Company.

 

    	19

    	 

    

 

IN WITNESS WHEREOF, the Company has duly executed this Subscription
Agreement as of the __ day of _______________, 2014.

 

	 	CERULEAN GROUP, INC.  (intended to be renamed

Enumeral Biomedical Holdings, Inc.)
	 	 	 
	 	By: 	 
	 		Name:
	 		Title:               Chief Executive Officer

 

    	20

    	 

    

 

How to subscribe for Units in the private
offering of

Cerulean
Group, Inc.  (intended
to be renamed Enumeral Biomedical Holdings, Inc.):

 

		1.	Date and Fill in the number of Units being purchased and complete and sign the Omnibus
Signature Page.

 

		2.	Initial the Investor Certification in the appropriate place or places.

 

		3.	Complete and sign the Investor Profile.

 

		4.	Complete and sign the Anti-Money Laundering Information Form.

 

		5.	Fax or email all forms and then send all signed original documents to:

 

Crone Kline Rinde LLP 488 Madison Avenue,
12th Floor

New York, NY 10022

Facsimile Number: (212) 400-6901

Telephone Number: (212) 400-6900

Attn:
Kathleen L. Rush

E-mail
Address: klr@CKRlaw.com

 

		6.	If you are paying the Purchase
                                         Price by check, a certified or other bank check for the exact dollar amount of
                                         the Purchase Price for the number of Units you are purchasing should be made payable
                                         to the order of “U.S. Bank National Association, as Escrow Agent for CERULEAN
                                         GROUP, INC., ACCT #_______” and should be sent directly to [______________________________].

 

		7.	If you are paying the Purchase Price by wire transfer, you should send a wire transfer
for the exact dollar amount of the Purchase Price for the number of Units you are purchasing according to the following instructions:

 

	Bank:	
        U.S. Bank National Association

        ____________________

        _____________________

	ABA Routing #:	__________
	SWIFT CODE:	__________
	Account Name:	__________________
	Account #:	________________
	Reference:	“__________: Cerulean Group, Inc. Escrow;

[_____] – [insert Subscriber’s name]”
	U.S. Bank Contact:	_____________

 

Thank you for your interest,

 

Cerulean Group, Inc.

 

    	 

    	 

    

 

CERULEAN
GROUP, INC.  (intended
to be renamed Enumeral Biomedical Holdings, Inc.)

OMNIBUS SIGNATURE PAGE TO

SUBSCRIPTION AGREEMENT, REGISTRATION RIGHTS
AGREEMENT AND THE VOTING AGREEMENT

 

The undersigned, desiring to: (i) enter into
the Subscription Agreement, dated as of ____________ ___,2 2014 (the “Subscription Agreement”),
between the undersigned, Cerulean Group, Inc., a Nevada corporation (the “Company”),
and the other parties thereto, in or substantially in the form furnished to the undersigned, (ii) enter into each of tthe Registration
Rights Agreement (the “Registration Rights Agreement”) and the Voting Agreement
(the “Voting Agreement”), among the undersigned, the Company and the other parties thereto, in or substantially in
the forms furnished to the undersigned and (iii) purchase the Units of the Company’s securities as set forth in the Subscription
Agreement and below, hereby agrees to purchase such Units from the Company and further agrees to join the Subscription Agreement,
the Registration Rights Agreement and the Voting Agreement as a party thereto, with all the rights and privileges appertaining
thereto, and to be bound in all respects by the terms and conditions thereof. The undersigned specifically acknowledges having
read the representations section in the Subscription Agreement entitled “Representations and Warranties of the Subscriber”
and hereby represents that the statements contained therein are complete and accurate with respect to the undersigned as a Subscriber.

 

IN WITNESS WHEREOF, the Subscriber hereby executes
this Subscription Agreement, the Registration Rights Agreement and the Voting Agreement.

 

Dated: ___________________, 2014

 

	 	 	X	 	$1.00	 	=	$ ______________
	Number of Units	 	 	 	Purchase Price per Unit	 	 	Total Purchase Price

 

	SUBSCRIBER (individual)	 	SUBSCRIBER (entity)
	 	 	 
	 	 	 
	Signature	 	Name of Entity
	 	 	 
	 	 	 
	Print Name	 	Signature
	 	 	 
	 	 	Print Name: 	 
	Signature (if Joint Tenants or Tenants in Common)	Title:	 	 
	 	 	 
	Address of Principal Residence:	 	Address of Executive Offices:
	 	 	 
	 	 	 
	 	 	 
	 	 	 
	Social Security Number(s):	 	IRS Tax Identification Number: 
	 	 	 
	 	 	 
	Telephone Number:	 	Telephone Number: 
	 	 	 
	 	 	 
	Facsimile Number:	 	Facsimile Number: 
	 	 	 
	 	 	 
	E-mail Address:	 	E-mail Address: 
	 	 	 
	 	 	 	 	 

 

2 Will reflect the
Closing Date. Not to be completed by Subscriber.

 

    	 

    	 

    

 

CERULEAN
GROUP, INC. (intended
to be renamed Enumeral Biomedical Holdings, Inc.)

ACCREDITED INVESTOR CERTIFICATION

 

For Individual Investors Only

(all Individual Investors must INITIAL
where appropriate):

 

	Initial _______ 	 	I have a net worth of at least US$1 million either individually or through aggregating my individual holdings and those in which I have a joint, community property or other similar shared ownership interest with my spouse. (For purposes of calculating your net worth under this paragraph, (a) your primary residence shall not be included as an asset; (b) indebtedness secured by your primary residence, up to the estimated fair market value of your primary residence at the time of your purchase of the securities, shall not be included as a liability (except that if the amount of such indebtedness outstanding at the time of your purchase of the securities exceeds the amount outstanding 60 days before such time, other than as a result of the acquisition of your primary residence, the amount of such excess shall be included as a liability); and (c) indebtedness that is secured by your primary residence in excess of the estimated fair market value of your primary residence at the time of your purchase of the securities shall be included as a liability.)
	 	 	 
	Initial _______	 	I have had an annual gross income for the past two years of at least US$200,000 (or US$300,000 jointly with my spouse) and expect my income (or joint income, as appropriate) to reach the same level in the current year.
	 	 	 
	Initial _______	 	I am a director or executive officer of Enumeral Biomedical Holdings, Inc.

 

For Non-Individual
Investors (Entities)

(all Non-Individual
Investors must INITIAL where appropriate):

 

	Initial _______	 	The investor certifies that it is a partnership, corporation, limited liability company or business trust that is 100% owned by persons who meet at least one of the criteria for Individual Investors set forth above (in which case each such person must complete the Accreditor Investor Certification for Individuals above as well the remainder of this questionnaire) . 
	 	 	 
	Initial _______	 	The investor certifies that it is a partnership, corporation, limited liability company or business trust that has total assets of at least US$5 million and was not formed for the purpose of investing the Company.
	 	 	 
	Initial _______	 	The investor certifies that it is an employee benefit plan whose investment decision is made by a plan fiduciary (as defined in ERISA §3(21)) that is a bank, savings and loan association, insurance company or registered investment advisor.
	 	 	 
	Initial _______	 	The investor certifies that it is an employee benefit plan whose total assets exceed US$5,000,000 as of the date of this Agreement.
	 	 	 
	Initial _______	 	The undersigned certifies that it is a self-directed employee benefit plan whose investment decisions are made solely by persons who meet at least one of the criteria for Individual Investors.
	 	 	 
	Initial _______	 	The investor certifies that it is a U.S. bank, U.S. savings and loan association or other similar U.S. institution acting in its individual or fiduciary capacity.
	 	 	 
	Initial _______	 	The undersigned certifies that it is a broker-dealer registered pursuant to §15 of the Securities Exchange Act of 1934.
	 	 	 
	Initial _______	 	The investor certifies that it is an organization described in §501(c)(3) of the Internal Revenue Code with total assets exceeding US$5,000,000 and not formed for the specific purpose of investing in the Company.
	 	 	 
	Initial _______	 	The investor certifies that it is a trust with total assets of at least US$5,000,000, not formed for the specific purpose of investing in the Company, and whose purchase is directed by a person with such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of the prospective investment.
	 	 	 
	Initial _______	 	The investor certifies that it is a plan established and maintained by a state or its political subdivisions, or any agency or instrumentality thereof, for the benefit of its employees, and which has total assets in excess of US$5,000,000.
	 	 	 
	Initial _______	 	The investor certifies that it is an insurance company as defined in §2(13) of the Securities Act of 1933, or a registered investment company.

 

    	 

    	 

    

 

CERULEAN
GROUP, INC.  (intended
to be renamed Enumeral Biomedical Holdings, Inc.)

Investor Profile

(Must be completed by Investor)

 

Section A - Personal Investor Information

 

Investor Name(s): _____________________________________________________________________________________

 

Individual executing Profile or Trustee: ____________________________________________________________________

 

Social Security Numbers / Federal I.D. Number: _____________________________________________________________

 

	Date of Birth:	 	 	Marital Status:  	 	 
	Joint Party Date of Birth: 	 	 	Investment Experience (Years):  	 
	Annual Income:	 	 	Liquid Net Worth:  	 	 
	 	 	 	 	 	 
	Net Worth*:	 	 	 	 	 
	 	 	 	 	 	 
	Tax Bracket:	_____ 15% or below                    _____ 25% - 27.5%                     _____ Over 27.5%

 

Home Street Address: __________________________________________________________________________________

 

Home City, State & Zip Code: ___________________________________________________________________________

 

Home Phone: ______________________   Home Fax: ______________________   Home
Email: _____________________

 

Employer: ___________________________________________________________________________________________

 

Employer Street Address: _______________________________________________________________________________

 

Employer City, State & Zip Code: ________________________________________________________________________

 

Bus. Phone: ________________________   Bus. Fax: ________________________   Bus.
Email: _____________________

 

Type of Business: _____________________________________________________________________________________

 

Outside Broker/Dealer: _________________________________________________________________________________

 

Section B – Certificate Delivery
Instructions

 

____ Please deliver certificate to the Employer Address listed
in Section A.

____ Please deliver certificate to the Home Address listed in Section A.

____ Please deliver certificate to the following address: __________________________________________________________

 

Section C – Form of Payment –
Check or Wire Transfer

 

____ Check payable to U.S. Bank National Association , as Escrow Agent for Cerulean Group, Inc.

____ Wire funds from my outside account according to Section 2(b) of the Subscription Agreement.

____ The funds for this investment are rolled over, tax deferred from __________ within the allowed 60 day window.

 

Please
check if you are a FINRA member or affiliate of a FINRA member firm: ____ 

 

	 	 	 
	Investor Signature	 	Date

 

		*	For purposes of calculating your net worth in this form, (a) your primary residence shall
not be included as an asset; (b) indebtedness secured by your primary residence, up to the estimated fair market value of your
primary residence at the time of your purchase of the securities, shall not be included as a liability (except that if the amount
of such indebtedness outstanding at the time of your purchase of the securities exceeds the amount outstanding 60 days before such
time, other than as a result of the acquisition of your primary residence, the amount of such excess shall be included as a liability);
and (c) indebtedness that is secured by your primary residence in excess of the estimated fair market value of your primary residence
at the time of your purchase of the securities shall be included as a liability. 

 

    	 

    	 

    

ANTI MONEY LAUNDERING REQUIREMENTS

 

The USA PATRIOT Act

 

The USA PATRIOT Act is designed to detect,
deter, and punish terrorists in the United States and abroad. The Act imposes new anti-money laundering requirements on brokerage
firms and financial institutions. Since April 24, 2002 all brokerage firms have been required to have new, comprehensive anti-money
laundering programs.

 

To help you understand these efforts, we want
to provide you with some information about money laundering and our steps to implement the USA PATRIOT Act.

 

What is money laundering?

 

Money laundering is the process of disguising
illegally obtained money so that the funds appear to come from legitimate sources or activities. Money laundering occurs in connection
with a wide variety of crimes, including illegal arms sales, drug trafficking, robbery, fraud, racketeering, and terrorism.

 

How big is the problem and why is it important?

 

The use of the U.S. financial system by criminals
to facilitate terrorism or other crimes could well taint our financial markets. According to the U.S. State Department, one recent
estimate puts the amount of worldwide money laundering activity at $1 trillion a year.

 

What are we required to do to eliminate
money laundering?

 

Under rules required by the USA PATRIOT Act,
our anti-money laundering program must designate a special compliance officer, set up employee training, conduct independent audits,
and establish policies and procedures to detect and report suspicious transaction and ensure compliance with such laws. As part
of our required program, we may ask you to provide various identification documents or other information. Until you provide the
information or documents we need, we may not be able to effect any transactions for you.

 

    	 

    	 

    

ANTI-MONEY
LAUNDERING INFORMATION FORM

The following is required in accordance with
the AML provision of the USA PATRIOT ACT.

(Please fill out and return with requested
documentation.)

 

	INVESTOR NAME:	 	 
	 	 	 
	LEGAL ADDRESS:	 	 
	 	 	 
	 	 	 
	SSN# or TAX ID#	 	 
	 OF INVESTOR: 	 	 
	 	 	 
	YEARLY INCOME: 	 	 
	 	 	 
	NET WORTH:  	 	  *

 

* For purposes of calculating your net worth
in this form, (a) your primary residence shall not be included as an asset; (b) indebtedness secured by your primary residence,
up to the estimated fair market value of your primary residence at the time of your purchase of the securities, shall not be included
as a liability (except that if the amount of such indebtedness outstanding at the time of your purchase of the securities exceeds
the amount outstanding 60 days before such time, other than as a result of the acquisition of your primary residence, the amount
of such excess shall be included as a liability); and (c) indebtedness that is secured by your primary residence in excess of the
estimated fair market value of your primary residence at the time of your purchase of the securities shall be included as a liability.

 

INVESTMENT OBJECTIVE(S):  _______________________________________________

 

ADDRESS OF BUSINESS OR OF EMPLOYER: __________________________________

 

_______________________________

 

FOR INVESTORS WHO ARE INDIVIDUALS:
AGE:  _____________________________

 

FOR INVESTORS WHO ARE INDIVIDUALS:
OCCUPATION: _____________________________________

 

FOR INVESTORS WHO ARE ENTITIES: TYPE
OF BUSINESS: ____________________________________

 

IDENTIFICATION & DOCUMENTATION
AND SOURCE OF FUNDS:

 

		1.	Please submit a copy of non-expired identification for the authorized signatory(ies) on the investment
documents, showing name, date of birth, address and signature. The address shown on the identification document MUST match the
Investor’s address shown on the Investor Signature Page.

 

	Current Driver’s License	or	Valid Passport	or	Identity Card

(Circle one or more)

 

		2.	If the Investor is a corporation, limited liability company, trust or other type of entity, please
submit the following requisite documents: (i) Articles of Incorporation, By-Laws, Certificate of Formation, Operating Agreement,
Trust or other similar documents for the type of entity; and (ii) Corporate Resolution or power of attorney or other similar document
granting authority to signatory(ies) and designating that they are permitted to make the proposed investment.

 

		3.	Please advise where the funds were derived from to make the proposed investment:

 

	Investments	Savings	Proceeds of Sale	Other ____________

(Circle one or more)

 

	Signature:	 
	 	 	 
	Print Name: 	 
	 	 	 
	Title (if applicable): 	 
	 	 	 
	Date:	 

 

    	 

    	 

    

 

Schedule 4a

 

Subsidiaries

 

    	 

    	 

    

 

Schedule 4c

 

Preemptive Rights; Options and Warrants;
Debt Securities; Registration Rights

 

(i) Preemptive Rights

 

(ii) Options and Warrants

 

(iv) Debt Securities

 

(v) Registration Rights

 

(vii)Anti-Dilution Provisions

 

    	 

    	 

    

 

Schedule 4e

 

Consents

 

    	 

    	 

    

 

Schedule 4k

 

Intellectual Property Rights

 

    	 

    	 

    

 

Schedule 4n

 

Title 

 

    	 

    	 

    

 

Schedule 4r

 

Rights of First Refusal 

 

    	 

    	 

    

 

Schedule 4t

 

Brokers’ Fees

 

    	 

    	 

    

 

EXHIBIT A

 

Form of Warrant

 

    	 

    	 

    

 

EXHIBIT B

 

Form of Registration Rights Agreement

 

    	 

    	 

    

 

EXHIBIT C

 

Form of Voting AgreementWarrant Certificate No. ______

 

NEITHER THE SECURITIES REPRESENTED HEREBY
NOR THE SECURITIES ISSUABLE UPON THE EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED
(THE “SECURITIES ACT”), OR ANY STATE SECURITIES LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED,
SOLD, PLEDGED, OR OTHERWISE TRANSFERRED UNLESS (1) A REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES
ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR (2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION
OF COUNSEL TO THE HOLDER OF SUCH SECURITIES, WHICH COUNSEL AND OPINION ARE SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY
BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER
THE SECURITIES ACT OR APPLICABLE STATE SECURITIES LAWS. HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED
UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

 

	Effective Date: _________, 2014	Expiration Date: __________, 2019

 

ENUMERAL BIOMEDICAL HOLDINGS, INC.

 

WARRANT TO PURCHASE COMMON STOCK

 

Enumeral Biomedical
Holdings, Inc. (formerly known as Cerulean Group, Inc.), a Delaware corporation (the “Company”),
for value received on the Effective Date, hereby issues to __________________________ (the “Holder”) this Warrant
(the “Warrant”) to purchase ______________ shares (as from time to time adjusted as hereinafter provided) (each
such share a “Warrant Share” and all such shares being the “Warrant Shares”) of the Company’s
Common Stock (as defined below), at the Exercise Price (as defined below), as adjusted from time to time as provided herein, on
or before the Expiration Date, all subject to the following terms and conditions.

 

This Warrant is one of
a series of Warrants of like tenor being issued to Subscribers in the Company’s private offering (the “Offering”)
of Units of its securities in accordance with, and subject to, the terms and conditions described in the Subscription Agreement
entered into by and between the Company and each Subscriber set forth on the signature pages affixed thereto (the “Subscription
Agreement”). Capitalized terms used herein without definition have the meanings ascribed to them in the Subscription
Agreement.

 

    	 

    	 

    

 

As used in this Warrant,
(i) “Business Day” means any day other than Saturday, Sunday or any other day on which commercial banks in the
City of New York, New York, are authorized or required by law or executive order to close; (ii) “Common Stock”
means the common stock of the Company, $0.001 par value per share, including any securities issued or issuable with respect thereto
or into which or for which such shares may be exchanged for, or converted into, pursuant to any stock dividend, stock split, stock
combination, recapitalization, reclassification, reorganization or other similar event; (iii) “Exercise Price”
means $2.00 per share of Common Stock, subject to adjustment as provided herein; (iv) “Trading Day” means any
day on which the primary national or regional stock exchange on which the Common Stock is listed, or if not so listed, the OTC
Bulletin Board or the OTC Markets, if quoted thereon, is open for the transaction of business;
and (v) “Affiliate” means any person that, directly or indirectly, through one or more intermediaries, controls,
is controlled by, or is under common control with, a person, as such terms are used and construed in Rule 144 promulgated under
the Securities Act of 1933, as amended (the “Securities Act”).

 

		1.	DURATION AND EXERCISE OF WARRANTS

 

(a)          Exercise
Period. The Holder may exercise this Warrant in whole or in part on any Business Day on or before 5:00 P.M., Eastern Time,
on the Expiration Date, at which time this Warrant shall become void and of no value.

 

(b)          Exercise
Procedures.

 

(i)          Cash.
While this Warrant remains outstanding and exercisable in accordance with Section 1(a), the Holder may exercise this Warrant in
whole or in part at any time and from time to time by:

 

(A)         delivery
to the Company of a duly completed and executed copy of the notice of exercise attached hereto as Exhibit A (the “Notice
of Exercise”), with the “CASH” payment option indicated;

 

(B)         surrender
of this Warrant to the Secretary of the Company at its principal offices or at such other office or agency as the Company may specify
in writing to the Holder; and

 

(C)         payment
of the then-applicable Exercise Price per share multiplied by the number of Warrant Shares being purchased upon exercise of the
Warrant (such amount, the “Aggregate Exercise Price”) made in the form of cash, or by wire transfer of immediately
available funds, certified check or bank draft payable in lawful money of the United States of America.

 

(ii)         Cashless.
In addition to the manner set forth in Section 1(b)(i), while this Warrant remains outstanding and exercisable in accordance with
Section 1(a), if a Registration Event occurs and is continuing (as such term is defined in the Registration Rights Agreement dated
as of the date hereof) or as the Company otherwise agrees, during such time as such Registration Event is not cured by the Company,
the Holder may, in its sole discretion, exercise all or any part of the Warrant in a “cashless” or “net-issue”
exercise (a “Cashless Exercise”) by:

 

(A)         delivery
to the Company of a duly completed and executed Notice of Exercise, with the “CASHLESS” payment option indicated;

 

    	2

    	 

    

 

(B)         surrender
of this Warrant to the Secretary of the Company at its principal offices or at such other office or agency as the Company may specify
in writing to the Holder;

 

whereupon the Holder shall
be entitled to receive a number of Warrant Shares calculated using the following formula:

 

	 	X	=	Y * (A - B)
	 	 	 	A

 

where:

 

		X =	the number of Warrant Shares to be issued to the Holder

 

		Y =	the number of Warrant Shares with respect to which the Warrant is being exercised as specified
in the Notice of Exercise

 

		A =	the fair value per share of Common Stock on the date of exercise of this Warrant

 

		B =	the then-current Exercise Price of the Warrant

 

Solely for the purposes of
this Section 1(b), “fair value” per share of Common Stock shall mean the average Closing Price (as defined below) per
share of Common Stock for the twenty (20) Trading Days immediately preceding the date on which the Notice of Exercise is deemed
to have been sent to the Company. “Closing Price” means, for any date, the price determined by the first of
the following clauses that applies: (a) if the Common Stock is then listed on a national securities exchange, the closing price
per share of the Common Stock for such date (or the nearest preceding date) on the primary exchange on which the Common Stock is
then listed; (b) if prices for the Common Stock are then quoted on the OTC Bulletin Board or any tier of the OTC Markets, the closing
bid price per share of the Common Stock for such date (or the nearest preceding date) so quoted; or (c) if prices for the Common
Stock are then reported in the “Pink Sheets” published by the National Quotation Bureau Incorporated (or a similar
organization or agency succeeding to its functions of reporting prices), the most recent closing bid price per share of the Common
Stock so reported. If the Common Stock is not publicly traded as set forth above, the “fair value” per share
of Common Stock shall be reasonably and in good faith determined by the Board of Directors of the Company as of the date which
the Notice of Exercise is deemed to have been sent to the Company.

 

For purposes of Rule 144
promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant Shares issued in a Cashless
Exercise transaction shall be deemed to have been acquired by the Holder, and the holding period for such shares shall be deemed
to have commenced, on the date this Warrant was originally issued.

 

    	3

    	 

    

 

(iii)        Upon
the exercise of this Warrant in compliance with the provisions of this Section 1(b), and except as limited pursuant to Section
1(b)(iv), the Company shall promptly issue and cause to be delivered to the Holder a certificate for the Warrant Shares for which
this Warrant was exercised. Each exercise of this Warrant shall be effective immediately prior to the close of business on the
date (the “Date of Exercise”) that the conditions set forth in Section 1(b)(i) or (ii) have been satisfied,
as the case may be. On or before the third (3rd) Business Day following the date on which the Company has received each
of the items specified in Section 1(b)(i) or 1(b)(ii), as applicable (the “Exercise Deliverables”), the Company
shall transmit an acknowledgment of receipt of the Exercise Deliverables to the Company’s transfer agent (the “Transfer
Agent”). On or before the fifth (5th) Business Day following the date on which the Company has received all
of the Exercise Deliverables (the “Share Delivery Date”), the Company shall (X) provided that the Warrant Shares
have been registered or that the Warrant Shares are eligible for sale under Rule 144 without restriction and that the Transfer
Agent is participating in The Depository Trust Company (“DTC”) Fast Automated Securities Transfer Program, upon the
request of the Holder and to the extent applicable, Holder’s supplying the Company with required Rule 144 documentation,
cause the Transfer Agent to credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to
such exercise to the Holder’s or its designee’s balance account with DTC through its Deposit Withdrawal Agent Commission
system, or (Y) if the Warrant Shares have not been registered and are not eligible for sale under Rule 144 without restriction
or if Transfer Agent is not participating in the DTC Fast Automated Securities Transfer Program, cause the Transfer Agent to issue
and dispatch by overnight courier to the address as specified in the Notice of Exercise, a certificate, registered in the Company’s
share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled
pursuant to such exercise.

 

The
Holder understands that prior to the Merger, the Company was a “shell company” as defined in Rule 12b-2 under the Securities
Exchange Act of 1934, as amended (the “Exchange Act”), and that upon the filing of a Current Report on
Form 8-K (the “Super 8-K) reporting the consummation of the Merger and the Transactions and otherwise containing Form 10
information discussed below, the Company will cease to be a shell company. Pursuant to Rule 144(i), securities issued by a current
or former shell company (that is, this Warrant and the Warrant Shares) that otherwise meet the holding period and other requirements
of Rule 144 nevertheless cannot be sold in reliance on Rule 144 until one year after the Company (a) is no longer a shell
company; and (b) has filed current “Form 10 information“ (as defined in Rule 144(i)) with the SEC reflecting that it
is no longer a shell company, and provided that at the time of a proposed sale pursuant to Rule 144, the Company is subject to
the reporting requirements of Section 13 or 15(d) of the Exchange Act and has filed all reports and other materials required to
be filed by Section 13 or 15(d) of the Exchange Act, as applicable, during the preceding 12 months (or for such shorter period
that the issuer was required to file such reports and materials), other than Form 8-K reports. As a result, the restrictive
legends on certificates for the Warrant and he Warrant Shares cannot be removed except in connection with an actual sale meeting
the foregoing requirements or pursuant to an effective registration statement.

 

Upon delivery of the Exercise
Deliverables, the Holder shall be deemed for all corporate purposes to have become the holder of record of the Warrant Shares with
respect to which this Warrant has been exercised, irrespective of the date of delivery of the certificates evidencing such Warrant
Shares.

 

    	4

    	 

    

 

(iv)        If
the Company shall fail for any reason or for no reason to issue or cause to be issued to the Holder, within five (5) Business Days
of receipt of the Exercise Deliverables, a certificate for the number of shares of Common Stock to which the Holder is entitled
and register or cause to be registered such shares of Common Stock on the Company’s share register or to credit or cause
to be credited the Holder’s balance account with DTC for such number of shares of Common Stock to which the Holder is entitled
upon the Holder’s exercise of this Warrant (in each case as provided above), and if on or after such fifth (5th)
Business Day the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in satisfaction
of a sale by the Holder of shares of Common Stock issuable upon such exercise that the Holder anticipated receiving from the Company
(a “Buy-In”), then the Company shall, within three (3) Business Days after the Holder’s request and in
the Holder’s discretion, either (i) pay cash to the Holder in an amount equal to the Holder’s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased (the “Buy-In Price”),
at which point the Company’s obligation to deliver a certificate for the shares of Common Stock to which the Holder would
have been entitled and register or cause to be registered such shares of Common Stock on the Company’s share register, or
to credit or cause to be credited the Holder’s balance account with DTC for such number of shares of Common Stock to which
the Holder would have been entitled, shall terminate, or (ii) promptly honor its obligation to deliver to the Holder a certificate
or certificates representing such shares of Common Stock and pay cash to the Holder in an amount equal to the excess (if any) of
the Buy-In Price over the product of (A) such number of shares of Common Stock, times (B) the fair value of the Common Stock on
the date of exercise.

 

(v)         Notwithstanding
the foregoing provisions of this Section 1(b), the Holder may not exercise this Warrant if and to the extent that such exercise
would require the Company to issue a number of shares of Common Stock in excess of its authorized but unissued shares of Common
Stock, less all amounts of Common Stock that have been reserved for issue upon the conversion of all outstanding securities convertible
into shares of Common Stock and the exercise of all outstanding options, warrants and other rights exercisable for shares of Common
Stock. If the Company does not have the requisite number of authorized but unissued shares of Common Stock to permit the Holder
to exercise this Warrant, then the Company shall use commercially reasonable efforts to obtain the necessary stockholder consent
to increase the authorized number of shares of Common Stock to permit such Holder to exercise this Warrant pursuant to Section
1(b)(i) or Section 1(b)(ii).

 

(vi)        The
delivery by (or on behalf of) the Holder of the Notice of Exercise and the applicable Exercise Price as provided above shall constitute
the Holder’s certification to the Company that its representations and warranties contained in Section 5 of the Subscription
Agreement, including without limitation the representation and warranty that the Holder is an “accredited investor,”
are true and correct as of the exercise date as if remade in their entirety (or, in the case of any transferee Holder that is not
a party to the Subscription Agreement, such transferee Holder’s certification to the Company that such representations are
true and correct as to such assignee Holder as of the exercise date).

 

(c)          Partial
Exercise. This Warrant shall be exercisable, either in its entirety or, from time to time, for part only of the number of Warrant
Shares referenced by this Warrant; provided, that any such partial exercise must be for an integral number of Warrant Shares. If
this Warrant is exercised in part, the Company shall issue, at its expense, a new Warrant, in substantially the form of this Warrant,
referencing such reduced number of Warrant Shares that remain subject to this Warrant.

 

    	5

    	 

    

 

(e)          Disputes.
In the case of a dispute as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the
Company shall promptly issue to the Holder the number of Warrant Shares that are not disputed and resolve such dispute in accordance
with Section 15.

 

		2.	ISSUANCE OF WARRANT SHARES

 

(a)          The
Company covenants that all Warrant Shares will, upon issuance in accordance with the terms of this Warrant, be (i) duly authorized,
fully paid and non-assessable, and (ii) free from all liens, charges and security interests, with the exception of claims arising
through the acts or omissions of any Holder and except as arising from applicable Federal and state securities laws.

 

(b)          The
Company shall register this Warrant upon records to be maintained by the Company for that purpose in the name of the record holder
of such Warrant from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner thereof
for the purpose of any exercise thereof, any distribution to the Holder thereof and for all other purposes.

 

(c)          The
Company will not, by amendment of its articles of incorporation, by-laws or through any reorganization, transfer of assets, consolidation,
merger, dissolution, issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance
of any of the terms to be observed or performed hereunder by the Company, but will at all times in good faith assist in the carrying
out of all the provisions of this Warrant and in the taking of all action necessary or appropriate in order to protect the rights
of the Holder to exercise this Warrant, or against impairment of such rights.

 

		3.	ADJUSTMENTS OF EXERCISE PRICE, NUMBER AND TYPE OF WARRANT SHARES

 

(a)          General.
The Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall be subject to adjustment from time
to time upon the occurrence of certain events described in this Section 3(a); provided, that notwithstanding the provisions
of this Section 3, the Company shall not be required to make any adjustment if and to the extent that such adjustment would require
the Company to issue a number of shares of Common Stock in excess of its authorized but unissued shares of Common Stock, less all
amounts of Common Stock that have been reserved for issue upon the conversion of all outstanding securities convertible into shares
of Common Stock and the exercise of all outstanding options, warrants and other rights exercisable for shares of Common Stock.
If the Company does not have the requisite number of authorized but unissued shares of Common Stock to make any adjustment, the
Company shall use its commercially reasonable efforts to obtain the necessary stockholder consent to increase the authorized number
of shares of Common Stock to make such an adjustment pursuant to this Section 3(a).

 

    	6

    	 

    

 

(i)          Subdivision
or Combination of Stock. In case the Company shall at any time subdivide (whether by way of stock dividend, stock split or
otherwise) its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately prior
to such subdivision shall be proportionately reduced and the number of Warrant Shares shall be proportionately increased, and conversely,
in case the outstanding shares of Common Stock of the Company shall be combined (whether by way of stock combination, reverse stock
split or otherwise) into a smaller number of shares, the Exercise Price in effect immediately prior to such combination shall be
proportionately increased and the number of Warrant Shares shall be proportionately decreased. The Exercise Price and the Warrant
Shares, as so adjusted, shall be readjusted in the same manner upon the happening of any successive event or events described in
this Section 3(a)(i).

 

(ii)         Dividends
in Stock, Property, Reclassification. If at any time, or from time to time, the holders of Common Stock (or any shares of stock
or other securities at the time receivable upon the exercise of this Warrant) shall have received or become entitled to receive,
without payment therefor:

 

(A)         any
shares of stock or other securities that are at any time directly or indirectly convertible into or exchangeable for Common Stock,
or any rights or options to subscribe for, purchase or otherwise acquire any of the foregoing by way of dividend or other distribution,
or

 

(B)         additional
stock or other securities or property (including cash) by way of spin-off, split-up, reclassification, combination of shares or
similar corporate rearrangement (other than shares of Common Stock issued as a stock split or adjustments in respect of which shall
be covered by the terms of Section 3(a)(i) above),

 

then and in each such case, the Exercise Price
and the number of Warrant Shares to be obtained upon exercise of this Warrant shall be adjusted proportionately, and the Holder
hereof shall, upon the exercise of this Warrant, be entitled to receive, in addition to the number of shares of Common Stock receivable
thereupon, and without payment of any additional consideration therefor, the amount of stock and other securities and property
(including cash in the cases referred to above) that such Holder would hold on the date of such exercise had such Holder been the
holder of record of such Common Stock as of the date on which holders of Common Stock received or became entitled to receive such
shares or all other additional stock and other securities and property. The Exercise Price and the Warrant Shares, as so adjusted,
shall be readjusted in the same manner upon the happening of any successive event or events described in this Section 3(a)(ii).

 

    	7

    	 

    

 

(iii)        Reorganization,
Reclassification, Consolidation, Merger or Sale. If any recapitalization, reclassification or reorganization of the capital
stock of the Company, or any consolidation or merger of the Company with another corporation or any other entity, or the sale of
all or substantially all of its assets or other transaction shall be effected in such a way that holders of Common Stock shall
be entitled to receive stock, securities or other assets or property (an “Organic Change”), then, as a condition
of such Organic Change, lawful and adequate provisions shall be made by the Company whereby the Holder hereof shall thereafter
have the right to purchase and receive (in lieu of the shares of the Common Stock of the Company immediately theretofore purchasable
and receivable upon the exercise of the rights represented by this Warrant) such shares of stock, securities or other assets or
property as may be issued or payable with respect to or in exchange for a number of outstanding shares of such Common Stock equal
to the number of shares of such stock immediately theretofore purchasable and receivable assuming the full exercise of the rights
represented by this Warrant. In the event of any Organic Change, appropriate provision shall be made by the Company with respect
to the rights and interests of the Holder of this Warrant to the end that the provisions hereof (including, without limitation,
provisions for adjustments of the Exercise Price and of the number of shares purchasable and receivable upon the exercise of this
Warrant and registration rights substantially the same as those provided for in the Registration Rights Agreement) shall thereafter
be applicable, in relation to any shares of stock, securities or assets thereafter deliverable upon the exercise hereof. The Company
shall not effect any such Organic Change unless, prior to the consummation thereof, the successor corporation or entity (if other
than the Company) resulting from such consolidation or merger or the corporation purchasing such assets shall assume by written
instrument reasonably satisfactory in form and substance to the Holder executed and mailed or delivered to the registered Holder
hereof at the last address of such Holder appearing on the books of the Company, the obligation to deliver to such Holder such
shares of stock, securities or assets as, in accordance with the foregoing provisions, such Holder may be entitled to purchase.
If there is an Organic Change, then the Company shall cause to be mailed to the Holder at its last address as it shall appear on
the books and records of the Company, at least ten (10) calendar days before the effective date of the Organic Change, a notice
stating the date on which such Organic Change is expected to become effective or close, and the date as of which it is expected
that holders of the Common Stock of record shall be entitled to exchange their shares for securities, cash, or other property delivered
upon such Organic Change; provided, that the failure to mail such notice or any defect therein or in the mailing thereof
shall not affect the validity of the corporate action required to be specified in such notice. The Holder is entitled to exercise
this Warrant during the 10-day period commencing on the date of such notice to the effective date of the event triggering such
notice. In any event, the successor corporation (if other than the Company) resulting from such consolidation or merger or the
corporation purchasing such assets shall be deemed to assume such obligation to deliver to such Holder such shares of stock, securities
or assets even in the absence of a written instrument assuming such obligation to the extent such assumption occurs by operation
of law.

 

    	8

    	 

    

 

(b)          Adjustment
of Exercise Price upon Issuance of Additional Shares of Common Stock. In the event the Company shall at any time prior to the
Expiration Date issue Additional Shares of Common Stock, as defined below, without consideration or for a consideration per share
less than the Exercise Price in effect immediately prior to such issue, then the Exercise Price shall be reduced, concurrently
with such issue, to a price (calculated to the nearest cent) determined by multiplying such Exercise Price by a fraction, (A) the
numerator of which shall be (1) the number of shares of Common Stock outstanding immediately prior to such issue plus (2) the number
of shares of Common Stock which the aggregate consideration received or to be received by the Company for the total number of Additional
Shares of Common Stock so issued would purchase at such Exercise Price; and (B) the denominator of which shall be the number of
shares of Common Stock outstanding immediately prior to such issue plus the number of such Additional Shares of Common Stock so
issued; provided that, (i) for the purpose of this Section 3(b), all shares of Common Stock issuable upon conversion or
exchange of convertible securities outstanding immediately prior to such issue shall be deemed to be outstanding, and (ii) the
number of shares of Common Stock deemed issuable upon conversion or exchange of such outstanding convertible securities shall be
determined without giving effect to any adjustments to the conversion or exchange price or conversion or exchange rate of such
convertible securities resulting from the issuance of Additional Shares of Common Stock that is the subject of this calculation.
For purposes of this Warrant, “Additional Shares of Common Stock” shall mean all shares of Common Stock issued
by the Company after the Effective Date (including without limitation any shares of Common Stock issuable upon conversion or exchange
of any convertible securities or upon exercise of any option or warrant, on an as-converted basis), other than: (i) shares
of Common Stock issued or issuable upon conversion or exchange of any convertible securities or exercise of any options or warrants
outstanding on the Effective Date after giving effect to the Merger; (ii) shares of Common Stock issued or issuable upon exercise
of the Warrants or the Placement Agent Warrants; (iii) shares of Common Stock issued or issuable by reason of a dividend,
stock split, split-up or other distribution on shares of Common Stock that is covered by Sections 3(a)(i) through 3(a)(iii) above;
(iv) shares of Common Stock issued in a registered public offering under the Securities Act; (v) shares of Common Stock issued
or issuable pursuant to the acquisition of another entity or business by the Company by merger, purchase of substantially all of
the assets or other reorganization or pursuant to a joint venture or technology license agreement, but not including a transaction
in which the Company is issuing securities primarily for the purpose of raising capital or to an entity whose primary business
is investing in securities; (vi) shares of Common Stock issued or issuable to officers, directors and employees of, or consultants
to, the Company pursuant to stock grants, option plans, purchase plans or other employee stock incentive programs or arrangements
approved by the Board of Directors, or upon exercise of options or warrants granted to such parties pursuant to any such plan or
arrangement; (vii) any securities issued or issuable by the Company pursuant to the Subscription Agreements; and (viii) securities
issued to financial institutions, institutional investors or lessors in connection with credit arrangements, equipment financings,
lease arrangements or similar transactions, in the aggregate not exceeding ten percent (10%) of the number of shares of Common
Stock outstanding at any time, and in case of clauses (iii) through (viii) above, such issuance is approved by a majority of disinterested
directors of the Company and includes no “death spiral” provision of any kind. The provisions of this Section
3(b) shall not operate to increase the Exercise Price.

 

Upon each adjustment of
the Exercise Price pursuant to the provisions of this Section 3(b), the number of Warrant Shares issuable upon exercise of this
Warrant shall be adjusted by multiplying a number equal to the Exercise Price in effect immediately prior to such adjustment by
the number of Warrant Shares issuable upon exercise of this Warrant immediately prior to such adjustment and dividing the product
so obtained by the adjusted Exercise Price.

 

Notwithstanding the foregoing,
the Exercise Price and the number of shares purchasable upon the exercise of this Warrant shall no longer be subject to adjustment
pursuant to this Section 3(b) if the Warrant has been transferred or sold subsequent to the Offering (other than transfers to trusts
or affiliates of such investors for the purpose of estate planning).

 

    	9

    	 

    

 

(c)          Certificate
as to Adjustments. Upon the occurrence of each adjustment or readjustment pursuant to this Section 3, the Company at its expense
shall promptly compute such adjustment or readjustment in accordance with the terms hereof and furnish to each Holder of this Warrant
a certificate setting forth such adjustment or readjustment and showing in detail the facts upon which such adjustment or readjustment
is based. The Company shall promptly furnish or cause to be furnished to such Holder a like certificate setting forth: (i) such
adjustments and readjustments; and (ii) the number of shares and the amount, if any, of other property which at the time would
be received upon the exercise of the Warrant.

 

(d)          Certain
Events. If any event occurs as to which the other provisions of this Section 3 are not strictly applicable but the lack of
any adjustment would not fairly protect the purchase rights of the Holder under this Warrant in accordance with the basic intent
and principles of such provisions, or if strictly applicable would not fairly protect the purchase rights of the Holder under this
Warrant in accordance with the basic intent and principles of such provisions, then the Company's Board of Directors will, in good
faith and subject to applicable law, make an appropriate adjustment to protect the rights of the Holder; provided, that
no such adjustment pursuant to this Section 3(d) will increase the Exercise Price or decrease the number of Warrant Shares as otherwise
determined pursuant to this Section 3.

 

		4.	TRANSFERS AND EXCHANGES OF WARRANT AND WARRANT SHARES

 

(a)          Registration
of Transfers and Exchanges. Subject to Section 4(c), upon the Holder’s surrender of this Warrant, with a duly executed
copy of the Form of Assignment attached as Exhibit B, to the Secretary of the Company at its principal offices or at such
other office or agency as the Company may specify in writing to the Holder, the Company shall register the transfer of all or any
portion of this Warrant. Upon such registration of transfer, the Company shall issue a new Warrant, in substantially the form of
this Warrant, evidencing the acquisition rights transferred to the transferee and a new Warrant, in similar form, evidencing the
remaining acquisition rights not transferred, to the Holder requesting the transfer.

 

(b)          Warrant
Exchangeable for Different Denominations. The Holder may exchange this Warrant for a new Warrant or Warrants, in substantially
the form of this Warrant, evidencing in the aggregate the right to purchase the number of Warrant Shares, which may then be purchased
hereunder, each of such new Warrants to be dated the date of such exchange and to represent the right to purchase such number of
Warrant Shares as shall be designated by the Holder. The Holder shall surrender this Warrant with duly executed instructions regarding
such re-certification of this Warrant to the Secretary of the Company at its principal offices or at such other office or agency
as the Company may specify in writing to the Holder.

 

(c)          Restrictions
on Transfers. This Warrant may not be transferred at any time without (i) registration under the Securities Act or (ii) an
exemption from such registration and, if requested by the Company, a written opinion of legal counsel addressed to the Company
that the proposed transfer of the Warrant may be effected without registration under the Securities Act, which opinion will be
in form and from counsel reasonably satisfactory to the Company.

 

    	10

    	 

    

 

(d)          Permitted
Transfers and Assignments. Notwithstanding any provision to the contrary in this Section 4, the Holder may transfer, with or
without consideration, this Warrant or any of the Warrant Shares (or a portion thereof) to the Holder’s Affiliates (as such
term is defined under Rule 144 of the Securities Act) without obtaining the opinion from counsel that may be required by Section
4(c)(ii), provided, that the Holder delivers to the Company and its counsel certification, documentation, and other assurances
reasonably required by the Company’s counsel to enable the Company’s counsel to render an opinion to the Company’s
Transfer Agent that such transfer does not violate applicable securities laws.

 

		5.	MUTILATED OR MISSING WARRANT CERTIFICATE

 

If this Warrant is mutilated,
lost, stolen or destroyed, upon request by the Holder, the Company will, at its expense, issue, in exchange for and upon cancellation
of the mutilated Warrant, or in substitution for the lost, stolen or destroyed Warrant, a new Warrant, in substantially the form
of this Warrant, representing the right to acquire the equivalent number of Warrant Shares; provided, that, as a prerequisite
to the issuance of a substitute Warrant, the Company may require satisfactory evidence of loss, theft or destruction as well as
an indemnity from the Holder of a lost, stolen or destroyed Warrant.

 

		6.	PAYMENT OF TAXES

 

The Company will pay all
transfer and stock issuance taxes attributable to the preparation, issuance and delivery of this Warrant and the Warrant Shares
(and replacement Warrants) including, without limitation, all documentary and stamp taxes; provided, however, that
the Company shall not be required to pay any tax in respect of the transfer of this Warrant, or the issuance or delivery of certificates
for Warrant Shares or other securities in respect of the Warrant Shares to any person or entity other than to the Holder.

 

		7.	FRACTIONAL SHARES

 

No fractional Warrant Shares
shall be issued upon exercise of this Warrant. Upon the full exercise of this Warrant, the Company, in lieu of issuing any fractional
Warrant Share, shall round up the number of Warrant Shares issuable to nearest whole share.

 

		8.	NO STOCK RIGHTS AND LEGEND

 

No holder of this Warrant,
as such, shall be entitled to vote or be deemed the holder of any other securities of the Company that may at any time be issuable
on the exercise hereof, nor shall anything contained herein be construed to confer upon the holder of this Warrant, as such, the
rights of a stockholder of the Company or the right to vote for the election of directors or upon any matter submitted to stockholders
at any meeting thereof, or give or withhold consent to any corporate action or to receive notice of meetings or other actions affecting
stockholders (except as provided herein), or to receive dividends or subscription rights or otherwise (except as provide herein).

 

    	11

    	 

    

 

Each certificate for Warrant
Shares initially issued upon the exercise of this Warrant, and each certificate for Warrant Shares issued to any subsequent transferee
of any such certificate, shall be stamped or otherwise imprinted with a legend in substantially the following form:

 

THE SECURITIES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY STATE SECURITIES
LAWS, AND NEITHER SUCH SECURITIES NOR ANY INTEREST THEREIN MAY BE OFFERED, SOLD, PLEDGED, OR OTHERWISE TRANSFERRED UNLESS (1) A
REGISTRATION STATEMENT WITH RESPECT THERETO IS EFFECTIVE UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS, OR
(2) AN EXEMPTION FROM SUCH REGISTRATION EXISTS AND THE COMPANY RECEIVES AN OPINION OF COUNSEL TO THE HOLDER OF SUCH SECURITIES,
WHICH COUNSEL AND OPINION ARE SATISFACTORY TO THE COMPANY, THAT SUCH SECURITIES MAY BE OFFERED, SOLD, PLEDGED, ASSIGNED OR TRANSFERRED
IN THE MANNER CONTEMPLATED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR APPLICABLE STATE SECURITIES
LAWS. HEDGING TRANSACTIONS INVOLVING THESE SECURITIES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE SECURITIES ACT.

 

		9.	REGISTRATION RIGHTS

 

The Holder shall be entitled
to the registration rights with respect to the Warrant Shares set forth in, and subject to the conditions of, the Registration
Rights Agreement.

 

		10.	NOTICES

 

All notices, consents,
waivers, and other communications under this Warrant must be in writing and will be deemed given to a party (a) on the date of
delivery, if delivered to the appropriate address by hand or by nationally recognized overnight courier service (costs prepaid);
(b) the date of transmission if sent by facsimile or e-mail with confirmation of transmission by the transmitting equipment if
such notice or communication is delivered prior to 5:00 P.M., New York City time, on a Trading Day, or the next Trading Day after
the date of transmission, if such notice or communication is delivered on a day that is not a Trading Day or later than 5:00 P.M.,
New York City time, on any Trading Day; (c) the date received or rejected by the addressee, if sent by certified mail, return receipt
requested, if to the registered Holder hereof; or (d) seven days after the placement of the notice into the mails (first class
postage prepaid), to the Holder at the address, facsimile number, or e-mail address furnished by the registered Holder to the Company
in accordance with the Subscription Agreement by and between the Company and the Holder or, if the registered Holder is not the
original purchaser of this Warrant, then as provided in the Form of Assignment delivered to the Company pursuant to Section 4(a)
in connection with the assignment of this Warrant to such Holder, or if to the Company, to it at:

 

    	12

    	 

    

 

Enumeral Biomedical Holdings, Inc.

One Kendall Square

Building 400, 4th Floor

Cambridge, Massachusetts 02139

Attn: Chief Executive Officer

Telephone Number: (617) 674-1865

E-mail Address: arthur@enumeral.com

 

(or to such other address, facsimile number,
or e-mail address as the Holder or the Company as a party may designate by notice to the other party in accordance with this Section
10) with a copy to

 

Duane Morris, LLP

100 High Street, Suite 2400

Boston, MA 02110-1724

Attention Jonathan Lourie, Esq.

Facsimile: 857-401-3089

Telephone Number: 857-488-4260

E-mail Address:
JLourie@duanemorris.com

 

		11.	SEVERABILITY

 

If a court of competent
jurisdiction holds any provision of this Warrant invalid or unenforceable, the other provisions of this Warrant will remain in
full force and effect. Any provision of this Warrant held invalid or unenforceable only in part or degree will remain in full force
and effect to the extent not held invalid or unenforceable.

 

		12.	BINDING EFFECT

 

This Warrant shall be binding
upon and inure to the sole and exclusive benefit of the Company, its successors and assigns, the registered Holder or Holders from
time to time of this Warrant and the Warrant Shares.

 

		13.	SURVIVAL OF RIGHTS AND DUTIES

 

This Warrant shall terminate
and be of no further force and effect on the earlier of 5:00 P.M., Eastern Time, on the Expiration Date or the date on which this
Warrant has been exercised in full.

 

		14.	GOVERNING LAW

 

This Warrant will be governed
by and construed under the laws of the State of New York without regard to conflicts of laws principles that would require the
application of any other law.

 

    	13

    	 

    

 

		15.	DISPUTE RESOLUTION

 

In the case of a dispute
as to the determination of the Exercise Price or the arithmetic calculation of the Warrant Shares, the Company shall submit the
disputed determinations or arithmetic calculations via facsimile within five (5) Business Days of receipt of the Notice of Exercise
giving rise to such dispute, as the case may be, to the Holder. If the Holder and the Company are unable to agree upon such determination
or calculation of the Exercise Price or the Warrant Shares within three Business Days of such disputed determination or arithmetic
calculation being submitted to the Holder, then the Company shall, at its sole discretion, within five (5) Business Days, submit
via facsimile (a) the disputed determination of the Exercise Price to an independent, reputable investment bank selected by the
Company and approved by the Holder, or (b) the disputed arithmetic calculation of the Warrant Shares to the Company’s independent,
outside accountant. The Company shall cause at its expense the investment bank or the accountant, as the case may be, to perform
the determinations or calculations and notify the Company and the Holder of the results no later than ten (10) Business Days from
the time it receives the disputed determinations or calculations; provided that, if such disputed determination or arithmetic calculation
being submitted by the Holder is determined to be incorrect, then the expense of the investment bank or the accountant shall be
the responsibility of the Holder. Such investment bank’s or accountant’s determination or calculation, as the case
may be, shall be final, binding and conclusive upon the parties thereto.

 

		16.	NOTICES OF RECORD DATE

 

Upon (a) any establishment
by the Company of a record date of the holders of any class of securities for the purpose of determining the holders thereof who
are entitled to receive any dividend or other distribution, or right or option to acquire securities of the Company, or any other
right, or (b) any capital reorganization, reclassification, recapitalization, merger or consolidation of the Company with or into
any other corporation or other entity, any transfer of all or substantially all the assets of the Company, or any voluntary or
involuntary dissolution, liquidation or winding up of the Company, or the sale, in a single transaction, of a majority of the Company’s
voting stock (whether newly issued, or from treasury, or previously issued and then outstanding, or any combination thereof), the
Company shall mail to the Holder at least ten (10) Business Days, or such longer period as may be required by law, prior to the
record date specified therein, a notice specifying (i) the date established as the record date for the purpose of such dividend,
distribution, option or right and a description of such dividend, option or right, (ii) the date on which any such reorganization,
reclassification, transfer, consolidation, merger, dissolution, liquidation or winding up, or sale is expected to become effective
and (iii) the date, if any, fixed as to when the holders of record of Common Stock shall be entitled to exchange their shares of
Common Stock for securities or other property deliverable upon such reorganization, reclassification, transfer, consolation, merger,
dissolution, liquidation or winding up.

 

    	14

    	 

    

 

		17.	RESERVATION OF SHARES

 

The Company shall reserve
and keep available out of its authorized but unissued shares of Common Stock for issuance upon the exercise of this Warrant, free
from pre-emptive rights, such number of shares of Common Stock for which this Warrant shall from time to time be exercisable. The
Company will take all such reasonable action as may be necessary to assure that such Warrant Shares may be issued as provided herein
without violation of any applicable law or regulation. Without limiting the generality of the foregoing, the Company covenants
that it will use commercially reasonable efforts to take all such action as may be necessary or appropriate in order that the Company
may validly and legally issue fully paid and non-assessable Warrant Shares upon the exercise of this Warrant and use commercially
reasonable efforts to obtain all such authorizations, exemptions or consents, including but not limited to consents from the Company’s
stockholders or Board of Directors or any public regulatory body, as may be necessary to enable the Company to perform its obligations
under this Warrant.

 

		18.	HEADINGS

 

The headings used in this
Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.

 

		19.	AMENDMENT AND WAIVERS

 

Any term of this Warrant
may be amended and the observance of any term of this Agreement may be waived (either generally or in a particular instance and
either retroactively or prospectively), with the written consent of the Company and the Holders of a majority of the Warrant Shares
issuable upon exercise of the Warrants.

 

		20.	NO THIRD PARTY RIGHTS

 

This Warrant is not intended,
and will not be construed, to create any rights in any parties other than the Company and the Holder, and no person or entity may
assert any rights as third-party beneficiary hereunder.

 

[SIGNATURE PAGE FOLLOWS]

 

    	15

    	 

    

 

IN WITNESS WHEREOF, the
Company has caused this Warrant to be duly executed as of the date first set forth above.

 

	 	ENUMERAL BIOMEDICAL HOLDINGS, INC.
	 	 	 
	 	By: 	 
	 	 	Name:
	 	 	Title:

 

    	 

    	 

    

 

EXHIBIT A

 

NOTICE OF EXERCISE

 

(To be executed by Holder of Warrant if Holder
desires to exercise Warrant)

 

To Enumeral Biomedical Holdings, Inc.:

 

The undersigned hereby irrevocably elects to
exercise this Warrant with respect to ___________________ shares of Common Stock (as defined in the Warrant) as follows:

 

Check applicable
box

 

		o	CASH: Number of shares of Common Stock
exercised X $2.00 per share = $_________ (to be paid as provided in Section 1(b)(i) of the Warrant) plus any applicable taxes payable
by the undersigned pursuant to the Warrant; or

 

		o	CASHLESS (if eligible in accordance with
Section 1(b)(ii) of the Warrant).

 

The undersigned requests that certificates for
such shares be issued in the name of:

_________________________________________

_________________________________________

_________________________________________

 

(Please print name, address and social security
or federal employer identification number (if applicable))*

 

If the shares issuable
upon this exercise of the Warrant are not all of the Warrant Shares which the Holder is entitled to acquire upon the exercise of
the Warrant, the undersigned requests that a new Warrant evidencing the rights not so exercised be issued in the name of and delivered
to:

_________________________________________

_________________________________________

_________________________________________

 

(Please print name, address and social security
or federal employer identification number (if applicable))*

 

	 	Name of Holder (print):	 

	 	(Signature):	 

	 	(By:)	 

	 	(Title:)	 

	 	Dated:	 

 

 

*          If Warrant Shares are to be issued in any name other than that
of the registered Holder of the Warrant, then the Holder must include an opinion of counsel, reasonably satisfactory to the Company,
to the effect that such issuance complies with all applicable securities laws.

 

    	 

    	 

    

 

EXHIBIT B

 

FORM OF ASSIGNMENT

 

FOR VALUE RECEIVED, ___________________________________
hereby sells, assigns and transfers to each assignee set forth below all of the rights of the undersigned under the Warrant (as
defined in and evidenced by the attached Warrant) to acquire the number of Warrant Shares set opposite the name of such assignee
below and in and to the foregoing Warrant with respect to said acquisition rights and the shares issuable upon exercise of the
Warrant:

 

	Name of Assignee

(and social security or federal

employer

identification number (if

applicable))	Address	Number of Shares
	 	 	 
	 	 	 
	 	 	 
	 	 	 

 

If the total of the Warrant
Shares are not all of the Warrant Shares evidenced by the foregoing Warrant, the undersigned requests that a new Warrant evidencing
the right to acquire the Warrant Shares not so assigned be issued in the name of and delivered to the undersigned.

 

	 	Name of Holder (print):	 

	 	(Signature):	 

	 	(By:)	 

	 	(Title:)	 

	 	Dated:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]